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Suicide gene therapy aims to improve selectivity of cancer treatment through 
expression of herpes simplex virus thymidine kinase (HSV-TK) in tumor cells, permitting 
phosphorylation of HSV-TK substrates with subsequent cytotoxic incorporation into 
DNA exclusively within the tumor.  This approach results in significantly greater 
cytotoxicity to cancer cells in a novel delayed manner when applied with the antiviral 
drug GCV as compared to other HSV-TK substrates.  To elucidate the mechanism for the 
unique cytotoxicity, DNA damage and the repair pathways involved in responding to this 
damage induced by GCV compared to related analogs were evaluated.  
Using phosphorylated histone H2AX (γ-H2AX) as a marker of DNA damage, 
GCV induced >7-fold more damage than a different HSV-TK substrate, 1-β-D-
arabinofuranosylthymine (araT), at equitoxic concentrations.  Although the number of γ-
H2AX foci decreased after removal of either drug, suggesting repair of these early 
lesions, only GCV produced a late and persistent increase in DNA damage indicating the 
induction of irreparable DNA damage.  Rad51 foci formed primarily following the late 
increase in γ-H2AX foci, exposure, implicating homologous recombination repair (HRR) 
in responding to GCV-induced lesions.  
A yeast-based screen of DNA damage response mutants was utilized to detect 
pathways nvolved in cytotoxicity with GCV.  Yeast deficient in HRR, cell cycle 
checkpoint, and mismatch repair (MMR) proteins all exhibited increased sensitivity to 
 x 
GCV.  Survival studies in human cells confirmed greater GCV sensitivity in MMR 
deficient cells, primarily at high concentrations, validating the yeast assay.  Thus, MMR 
and HRR may prevent cytotoxicity with ganciclovir.  
Previous reports suggested that GCV is genotoxic.  DNA mutations induced by 
GCV were characterized and compared to those resulting from treatment with two other 
structurally similar HSV-TK substrates, D-carbocyclic 2'-deoxyguanosine (CdG) and 
penciclovir (PCV).   GCV induced a dose-dependent increase in mutation frequency, 
while highly cytotoxic concentrations of CdG and PCV failed to increase mutations.  
GCV predominantly induced GC TA transversions which were significantly less 
frequent in control cells or those treated with PCV or CdG.  Analysis of cell cycle 
progression revealed different mechanisms of cell cycle arrest for each of these drugs.  
Thus, alteration of the deoxyribose structure produced profound differences in DNA 
replication and its fidelity, resulting in striking differences in cytotoxicity.  These data 
demonstrate that GCV induces significantly more DNA damage, which may not be 
repaired effectively by HRR and MMR, leading to multi-log cytotoxicity through 







Ganciclovir (GCV) is an anti-viral agent used clinically for herpesvirus infections 
that is also employed in a suicide gene therapy strategy for cancer.  Compared to other 
structurally related compounds, GCV has a unique ability to induce multi-log cytotoxicity 
in human tumor cells in vitro at submicromolar doses.  Although previous studies have 
contributed to the understanding of the mechanism by which GCV elicits cell killing, the 
mechanism of GCV’s superior cytotoxicity has yet to be determined.  The data presented 
here provide further insights into the mechanism of GCV-mediated cytotoxicity by 
characterizing the induction of DNA damage by GCV and repair pathways involved in 
responding to this damage. 
 
Ganciclovir as an Antiviral Agent 
 The herpesvirus family consists of eight members which infect humans and cause 
a variety of illnesses ranging from cold sores to chickenpox to encephalitis (1-3).  
Herpesvirus infected cells express a virally encoded thymidine kinase which can 
accelerate viral replication by maintaining high levels of phosphorylated thymidine 
metabolites which are necessary for replication (4).  Compared to mammalian 
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thymidine kinase, herpes thymidine kinases have a broader range of substrate specificity, 
and can phosphorylate a variety of nucleoside analogs in addition to thymidine.   
In 1977, vidarabine (9-β-D-ribofuranosyladenine, araA) was the first 
antiherpesvirus agent approved for systemic use, but high toxicities induced by the drug 
limited its use to life-threatening infections (5,6).  Antiviral research seeking to develop 
new anti-herpetic drugs with low toxicity to host cells led to the discovery of a group of 
acyclic nucleoside analogs which are specifically phosphorylated by the viral thymidine 
kinase (7).  An important drug discovered from this study, acyclovir (9-[2-
hydroxyethoxymethyl]guanine; ACV), was the first truly selective drug with clinical 
activity against herpesvirus infections (8) and is currently in use today, where it is the 
drug of choice for a number of herpes infections (9).  ACV is an analogue of 2'-
deoxyguanosine with an acyclic sugar, lacking a 2'- and 3'-carbon and 3'-hydroxyl 
(Figure 1.1).   A compound developed a few years after acyclovir to more closely 
resemble deoxyguanosine, ganciclovir (9-[(1,2-dihydroxy-2-propoxymethyl)-guanine], 
GCV), is similar in structure to ACV with the addition of a hydroxymethyl group at the 
3´ position.  This addition of a 3' carbon allows GCV to be internally incorporated into 
DNA (10,11), unlike ACV which is an obligate chain terminator (12).   
The favorable therapeutic index for ACV and GCV is based on their selective 
activation in herpesvirus-infected cells, as these drugs undergo their requisite 
phosphorylation only in virally-infected cells expressing herpes simplex virus thymidine 
kinase (HSV-TK).  GCV is a better substrate than acyclovir for HSV-TK (Km= 66 µM 
and 426 µM, respectively) (13); however they are poorer substrates than thymidine (Km= 










Figure 1.1 Structure of 2'deoxyguanosine, acyclovir, and ganciclovir. 






















Subsequent phosphorylation by the cellular enzymes guanylate kinase and 
nucleoside diphosphokinase lead to the accumulation of GCV 5'-triphosphate (GCVTP) 
(10,14-17).  GCVTP inhibits viral replication by interfering with viral DNA synthesis but 
unphosphorylated GCV does not interrupt DNA synthesis, thus uninfected cells which do 
not contain GCVTP are not affected (18).  In vitro, GCV exhibits excellent antiviral 
activity against herpes simplex virus type 1 and 2 (13,19), human herpesvirus-6 (20,21), 
varicella-zoster virus (13), and Epstein-Barr virus (13,22) and is more potent than 
acyclovir against these viruses (10,23). 
In 1988, GCV was the first antiviral drug to be approved for the treatment of 
cytomegalovirus (CMV) infections in humans (24).  CMV lacks thymidine kinase, but 
phosphorylation to GCVMP is mediated by a protein kinase encoded by the CMV UL97 
gene (25,26).  Because ACV is poorly phosphorylated by UL97 kinase, CMV is 100-fold 
less sensitive to ACV than herpes simplex virus, and it is not possible to reach sufficient 
plasma concentrations required for therapeutic activity (27).  While CMV is usually an 
innocuous infection in immunocompetent patients, CMV infections can result in vision 
loss or fatality in patients with compromised immune systems, such as transplant 
recipients (reviewed in (28,29)) and those with AIDS (30).  Prophylaxis with anti-viral 
drugs, such as ACV and GCV, is commonly used in solid organ transplant patients to 
prevent CMV infections and the associated clinical syndrome.  Without prophylaxis with 
GCV, evidence of CMV infections occurred in more than 50% of recipients of solid 
organ transplants (31) and 7-32% presented with significant CMV disease (32).  GCV 
prophylaxis has reduced both the relative risk of CMV disease and mortality following 
organ transplant by 60% and 40%, respectively (reviewed in (33,34)). 
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Pharmacokinetics of GCV 
 Oral bioavailablity of GCV is poor, and thus it is usually administered by 
intravenous infusion (35).   GCV has been given orally, although the very high doses 
required to achieve effective plasma concentrations has made this route of administration 
unattractive.   The L-valyl ester prodrug of GCV, valganciclovir is transported into the 
bloodstream through peptide transporters PEPT1 and PEPT2 where it is rapidly and 
completely hydrolyzed to GCV by liver and intestinal esterases (36).  Valganciclovir is 
significantly more bioavailable (60.9% versus 5.6% for oral ganciclovir) (37-39) with no 
new toxicities occurring following treatment with the prodrug.  Clinically, plasma 
concentrations of 10-30 µM GCV have been reported (40-42).  GCV concentrations in 
cerebrospinal fluid were 31 to 67% of plasma concentrations, and intraocular 
concentrations were similar to or higher than plasma levels.  The primary route of 
elimination of GCV is through the kidney where almost 100% is excreted mainly as 
unchanged drug in the urine, with a terminal half-life of 4.5 hours (35).   
  Effective inhibitory concentrations of GCV for the herpes viruses range from 0.2 
to 6.0 µM while much higher concentrations are required to cause toxicity to most normal 
host tissues (41).  The notable exception is bone marrow cells, which are sensitive to 
concentrations of GCV similar to virus-infected cells, resulting in neutropenia in 15 - 
40% of patients and thrombocytopenia in 5 - 20% (41,43).  In addition to 
myelosuppression, CNS side effects ranging from headache to convulsions to coma occur 
in 5-15% of patients.  Conversely, clinically relevant doses of ACV do not produce 
myelosuppression and, unlike GCV, ACV is generally well-tolerated with minimal and 
infrequently reported side effects, such as nausea, diarrhea, headache, or more 
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infrequently renal dysfunction (44).  Because GCV has a much higher risk of causing 
dose-limiting bone marrow toxicity, it is typically reserved for treating life or sight 
threatening CMV infections (35,41).   
 
Cancer Gene Therapy 
 Many traditional chemotherapeutic drugs to treat cancer have limited ability to 
distinguish cancerous cells from normal host cells.  These therapies target cells based on 
their ability to proliferate, which does not allow distinction between neoplastic cells and 
many normal tissues in which cells are actively proliferating (bone marrow, 
gastrointestinal tract).  This results in many deleterious effects associated with such 
treatments, such as bone marrow suppression, gastrointestinal toxicity, and neuropathy, 
which are responsible for significant morbidity and mortality and a very narrow 
therapeutic index.  This limitation has led to the search for new therapies which increase 
the therapeutic index by selectively targeting tumor cells while sparing normal tissue 
from damage.    
 To improve the selectivity of cancer treatment, many cancer gene therapy 
strategies have been developed.  Examples include transduction of drug-resistance genes 
into bone marrow stem cells to protect them from chemotherapy (45-49), immunotherapy 
using recombinant DNA tumor cell vaccines (50-54), tumor suppressor gene replacement 
(55,56), and inactivation of oncogenes (57,58).  In suicide gene therapy, which are the 
most frequently studied strategies, tumor cells are engineered to express a foreign gene 
which encodes an enzyme that can convert a non-toxic pro-drug into a cytotoxic 
metabolite.  Since the drugs used in these therapies have lower toxicity than traditional 
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chemotherapeutics, they are selective for the virally-transduced tumor cells while sparing 
host tissues.  This allows the patient to be treated with higher doses of the agent to 
achieve tumor regression while limiting the side effects which normally occur in patients 
undergoing cancer chemotherapy.  Some examples of enzyme/pro-drug gene therapy 
include cytosine deaminase/5-fluorocytosine (59-61), nitroreductase/CB1954 (59), purine 
nucleoside phosphorylase/6-methyl-purine-2'-deoxynucleoside (62), and herpes simplex 
virus-thymidine kinase/GCV. 
 
Herpes Simplex Virus Type-1 Thymidine Kinase/Ganciclovir Gene Therapy 
 Perhaps the most widely studied suicide gene therapy strategy for cancer 
treatment utilizes the herpes simplex virus type 1 thymidine kinase (HSV-TK) with GCV.   
This strategy was first described by Frederic Moolten in 1986 and 1987 (63,64), and in 
1990 initial studies of this gene therapy approach were reported (65,66).  Studies have 
since progressed from in vitro evaluation to animal models and ultimately to many 
clinical trials.  
GCV is transported into mammalian cells via the nucleoside transporter and 
purine nucleobase transporter in erythrocytes (67-70).  Once inside HSV-TK-expressing 
cells, GCV is phosphorylated to GCVMP by HSV-TK (13).  The subsequent 
phosphorylation events to GCV diphosphate (GCVDP) and GCVTP are performed by 
mammalian guanylate kinase and nucleoside diphosphokinase, respectively (10,14-17).  
GCVTP competes with dGTP for incorporation into DNA, and this incorporation leads to 
cell death (71).   
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An important feature of this therapy is that HSV-TK-expressing cells can induce 
GCV-mediated cytotoxicity in neighboring tumor cells that do not express the transgene.  
This phenomenon, known as the bystander effect, has been observed both in vitro and in 
vivo (72-75).  Because currently it is only possible to transduce less than 1% of cells in 
patient tumors (76), the bystander effect is critical for the effectiveness of this approach.  
 Much research has focused on understanding the mechanism(s) of the bystander 
effect.   Freeman et al performed co-culture experiment in which HSV-TK-expressing 
and non-HSV-TK expressing cells were cultured in a dish with two chambers separated 
by a membrane, so that they shared the same media, but did not have physical contact.  
Following exposure to GCV, the non-transduced cells did not die.  However, when the 
same experiment allowed for contact between the HSV-TK expressing and non-HSV-TK 
expressing cells, it resulted in death of the non-transduced cells (77).  Another study 
demonstrated that exposing non-HSV-TK expressing cells to conditioned media from 
cells expressing HSV-TK and treated with [3H]GCV did not result in transfer of 
radioactivity or cytotoxicity to the non-HSV-TK expressing cells (78).  These studies 
suggest that cell-cell contact and transfer of a GCV metabolic product is required for the 
bystander effect.   
Phosphorylated GCV metabolites cannot freely diffuse through the cell 
membrane, however they can transfer between cells through gap junctions which are 
intercellular channels composed of two transmembrane hemichannels of connexin 
protein.  When these channels from neighboring cells dock together, they form a central 
pore, allowing for the transfer of various molecules ≤1 kDa in molecular weight 
[reviewed in (79)].  The transfer of GCV phosphates between cells allows for 
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neighboring, non-transduced cells to accumulate the active GCV metabolite, GCVTP, 
and ultimately die.  Although it has been reported that cells with good gap junction 
intracellular communication exhibit good bystander cytotoxicity (73,74,80,81), and cell 
lines that reportedly lack gap junctions do not exhibit bystander killing (82-85), bystander 
cytotoxicity has been observed in cells which do not express known connexin proteins, 
such as SW620 colon carcinoma cells (75).     In HeLa cells, which also lack expression 
of known connexin proteins, GCV phosphates were transferred between cells via a 
mechanism that appeared to require cell contact.  It was suggested that cells may express 
a low level of gap junctional intercellular communication that mediates transfer of small 
amounts of GCV phosphates to bystander cells (85).   
The bystander effect also has been explained by other mechanisms.  One 
hypothesis suggests that apoptotic vesicles generated during the death of HSV-TK 
expressing cells contain GCV metabolites and are phagocytosed by non-HSV-TK 
expressing cells (77).  It has also been proposed that multidrug resistance proteins, MRP-
4 and MRP-5, which can efflux phosphorylated nucleotides (86,87), might also efflux 
phosphorylated GCV metabolites (88), however this would require a mechanism able to 
transport phosphorylated compounds into cells.  The wealth of data demonstrating that 
cell-to-cell contact is required for the bystander effect suggest that gap junctions are the 
most likely candidates responsible for the bystander effect. 
 
Strategies to Improve HSV-TK/GCV Suicide Gene Therapy 
Because current gene transfer efficiencies are inadequate for treatment with HSV-
TK/GCV, many laboratories have focused on strategies to improve viral transduction by 
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modifying viral vectors and vector delivery (89-92).  HSV-TK mutants have been 
engineered to increase specificity for GCV, such that tumor growth inhibition or 
regression can be achieved with lower doses of GCV.  HSV-TK has a high affinity for 
thymidine (Km = 0.5µM) (93), while affinity for GCV is significantly lower (Km = 45 
µM) (13,94).  Black et al identified HSV-TK mutants with improved selectivity for GCV 
through random mutagenesis of the cDNA with selection in E. coli.  When expressed in 
mammalian cells, these HSV-TK mutants enhanced sensitivity to GCV by increasing 
GCV phosphorylation and decreasing sensitivity of the enzyme to thymidine (95).  One 
of the mutants (SR39) had an 83-fold higher specificity for GCV compared to  thymidine, 
resulting in a 294-fold decrease in the IC50 for GCV (96).  Subsequent work 
demonstrated that these mutants increased GCV-mediated cell killing in mammalian cells 
and tumor models (97-100).  Mutants with increased specificity for GCV should allow 
for the administration of lower concentrations of GCV to achieve sufficient GCVTP 
levels in HSV-TK expressing tumor cells.    This will not only allow for lower GCV 
concentrations to achieve higher tumor cell-killing but may also decrease GCV-associate 
side effects. 
Since most cancers are typically treated with a combination of drugs and 
therapeutic modalities, other groups have focused on improving GCV cytotoxicity 
through combination therapies.  Findings that demonstrated the existence of an anti-
tumor immune response following HSV-TK/GCV therapy prompted studies combining 
the expression of cytokines, such as interleukin-2, to enhance this immune response with 
the enzyme-prodrug gene therapy resulting in increased tumor cell killing.  Interleukin-2 
has been combined with HSV-TK/GCV alone or with other cytokines and has resulted in 
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a 2- to 3-fold reduction in tumor volume in a variety of tumor models (101-105).  The 
addition of interleukin-12 also enhanced anti-tumor immune response in combination 
with HSV-TK/GCV in animal models for colon and hepatocellular carcinoma (106-108).  
A clinical trial has shown that combining HSV-TK/GCV gene therapy and cytokines is 
safe, but the effectiveness and improvement over HSV-TK/GCV gene therapy alone has 
yet to be determined in humans (109).  
Cell cycle effects of certain agents have been used to enhance GCV cytotoxicity.  
Pre-treatment with polyamine biosynthesis inhibitor 2-difluoromethylornithine resulted in 
accumulation of cells in S phase and addition of GCV when this compound is removed 
allows for increased GCV incorporation into DNA (110,111).  Protein kinase C class 
inhibitor UCN-01 has been shown to abrogate camptothecin-induced S phase block, 
resulting in increased cytotoxicity and has also been shown to increase sensitivity to 
GCV (112).   
Because GCV inhibits DNA polymerase δ (113), which is involved in DNA 
repair, it was hypothesized that the combination of GCV with other DNA damaging 
agents would result in synergistic cytotoxicity.  Alkylating agent temozolomide, 
topoisomerase I inhibitor topotecan, and a dual suicide gene therapy strategy of 
cytochrome P450 2B1/cyclophosphamide have been reported to enhance cytotoxicity 
when combined with HSV-TK/GCV (114-118).  While the data presented in these reports 
are statistically significant, they represent less than a 2-fold increase in cell killing and 
thus may not be clinically significant. 
Other drugs which enhance GCV cytotoxicity include ribonucleotide reductase 
inhibitors hydroxyurea (75,119,120) and gemcitabine (121) which decrease dGTP pools, 
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resulting in increased GCVMP incorporation into DNA.  Similarly, thymidylate synthase 
inhibition with (E)-5-(2-bromovinyl)-2'-deoxyuridine or 5-fluorouracil (122) decreases 
HSV-TK substrate thymidine and results in increased GCVTP.  Several studies have 
combined cytosine deaminase/5-fluorocytosine, a 5-fluorouracil prodrug, and HSV-
TK/GCV strategies and have shown that this is more effective compared with the use of 
either strategy alone (123-127), with optimal synergy occurring when 5-fluorocytosine 
was sequenced 24 hr prior to GCV (127).  This therapy can be further enhanced by the 
addition of radiation (128,129).   
The effectiveness of HSV-TK/GCV in vitro and in animal models has prompted 
many other clinical trials in the last two decades in a variety of malignancies, including 
glioblastoma (130-133), mesothelioma (134), ovarian (135,136), and prostate cancer 
which exhibited the most promising results (137-143).  The major limiting factor for the 
effectiveness of this therapy is the ability to transduce a sufficient proportion of cells in 
the tumor.  A phase III clinical trial for HSV-TK/GCV gene therapy for glioblastoma 
reported transduction efficiency was below 0.002% in all patients (144).  Another study 
including 51 patients reported a maximum transduction efficiency of 2.6% in two patients 
with a value less than 0.03% in most patients (145).   
One experimental protocol in clinical trials utilizes a three-pronged approach for 
treating prostate cancer which includes (a) an oncolytic, replication competent 
adenovirus, (b) combined cytosine deaminase/5-fluorocytosine and HSV-TK/GCV gene 
therapy, and (c) radiation therapy (125,139,141,142,146).  Results from a preclinical 
model have been published recently extending this approach for the treatment of 
pancreatic cancer, and a Phase I trial in this malignancy is currently being conducted 
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(147). While the results from these studies have been promising, they have not been 
overwhelmingly successful, most likely due to the limitation of viral transduction.   
 A more recent application of the HSV-TK/GCV suicide gene therapy strategy is 
being developed as a means to control graft-versus-host disease (GVHD).   GVHD is a T 
cell-mediated complication in patients with leukemia undergoing allogeneic bone marrow 
transplantation that is a major cause of transplant-related morbidity and mortality (148).  
GVHD is the result of the recognition of host antigens by donor T lymphocytes which 
results in activation of macrophages, secretion of inflammatory cytokines, and apoptosis 
of host cells (149).  In this approach, retroviruses are used to stably transduce the HSV-
TK gene into donor T lymphocytes ex vivo prior to donor lymphocyte infusion or 
transplantation. When GVHD develops, GCV is administered, resulting in the death of 
HSV-TK positive T lymphocytes.  This approach has been shown to be very effective at 
suppressing GVHD in mouse models (150-154).  Several small clinical trials have 
produced promising results, showing reduced GVHD after GCV administration (155-
159) and a phase III clinical trial is scheduled to begin soon (160).  Because it is possible 
to select for HSV-TK-expressing cells by cell sorting prior to transplantation, 100% of 
the transplanted T lymphocytes can be engineered to express HSV-TK, and viral 
transduction is not a limitation as is the case with solid tumors.  If the selective killing of 
transduced T lymphocytes will be able to control GVHD without increasing rate of 
relapse, as has been observed in mouse models, this application of HSV-TK/GCV suicide 




Mechanisms of HSV-TK/GCV-Mediated Cell Killing 
 Rubsam et al previously reported on the superior cytotoxicity of GCV as 
compared to other HSV-TK substrates (71).  GCV induces >4 logs of cell kill whereas 
most other nucleoside analogues are only able to cause 1-2 logs of cell kill under similar 
conditions.  It was determined that the superior cytotoxicity of GCV as compared with 
other HSV-TK substrates 1-β-D-arabinofuranosylthymine (araT) and acyclovir was not 
due to increased accumulation of active triphosphate metabolite, increased incorporation 
into DNA, or increased apoptosis.  By staining DNA with propidium iodide, it was 
determined that GCV induced a unique manner of cell death where cells were able to 
complete one cell division cycle during and following GCV exposure; however, as they 
attempted to traverse S phase for a second time, they arrested and subsequently died.   
Conversely, cells treated with araT arrested in the first S phase during drug exposure.  
These data suggest that an event occurring during the second S phase following GCV 
exposure is responsible for cytotoxicity. 
 Because GCV elicits cell killing through incorporation into DNA in S phase, it 
was of interest to determine specific types of DNA damage induced by GCV.  Thust et al 
have published reports showing that GCV induces sister chromatid exchanges (SCEs) 
and structural chromosome aberrations while acyclovir and penciclovir did not (161).  
SCEs can arise as a result of homologous recombination (162-164), so these data 
suggested that DNA damage induced by GCV induced homologous recombination repair 
(HRR) to repair this damage.  Interestingly, SCE induction occurred during the second 
cell cycle following GCV treatment, similar timing to the S phase arrest Rubsam et al 
observed (71).  Taken together, these data suggest an event occurring during this second 
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S phase is responsible for GCV’s superior cytotoxicity.  Because GCV elicits its action 
by incorporating into DNA, it is possible that as cells attempt DNA synthesis, the 
presence of GCVMP in template DNA causes irreparable damage which is responsible 
for GCV’s high degree of cytotoxicity.     
There have been a few studies reporting the effects of GCV exposure in vitro, 
aimed at determining the mechanism of GCV-mediated cytotoxicity.  A study in B16 
murine melanoma cells indicated GCV induced a morphological change in cells due to 
the reorganization of components of the cytoskeleton as well as an accumulation of cells 
in G2/M after a 48-72 hr incubation (165).  It has also been reported that GCV treatment 
results in a decline in Bcl-2 levels and activation of caspases, leading to apoptosis (166).  
However, GCV and araT induced apoptosis to a similar extent (71).  Thus, while these 
studies highlight pathways utilized by GCV that lead to cell death, they do not address 
the mechanism(s) by which GCV is significantly more cytotoxic than most other HSV-
TK substrates.   
 
DNA Damage Response Pathways 
In response to numerous DNA-damaging insults, cells have evolved complex 
mechanisms to monitor and repair DNA lesions in order to maintain genomic integrity.  
DNA damage is sensed by highly conserved signaling pathways which involve protein 
kinases such as ataxia-telangiectasia mutated (ATM) and ataxia-telangiectasia and Rad3-
related (ATR) to recognize DNA lesions and activate cell cycle checkpoints which trigger 
cellular responses including activation of DNA repair machinery and cell-cycle arrest 
(167).   
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Dependent upon the type of damage, different protein repair complexes are 
involved in the overall cellular response (reviewed in (168)).  DNA bases that are altered 
by small chemical modifications, such as oxidations, alkylations, or deaminations, are 
removed by base excision repair (BER), which excises 2-13 nucleotides containing the 
altered nucleotide.  DNA polymerases then replace the removed nucleotides.  In a method 
similar to that of BER, nucleotide excision repair (NER) is responsible for the repair of 
DNA bases containing bulky chemical adducts or cross-links.   The mismatch repair 
(MMR) pathway is involved in the repair of mispaired nucleotides and small 
insertion/deletion loops created by DNA polymerase errors during replication. 
Double-strand breaks (DSBs) are a particularly hazardous type of damage because 
they can lead to genome rearrangements, and two mechanisms exist to repair these 
lesions: non-homologous end joining (NHEJ) and HRR.  A distinguishing feature 
between the DNA DSB pathways is the requirement of HRR for a sister chromatid 
present in the S/G2 phase of replicating cells, implying that the repair of DSBs in non-
replicating cells occurs via NHEJ.  HRR is an error-free process that uses a sister 
chromatid as template DNA to achieve precise repair (169,170).  In contrast to HR, 
NHEJ is an error-prone DSB repair mechanism that facilitates joining of broken DNA 
ends (171). 
Translesion synthesis allows replication machinery to replicate past damaged 
DNA.  This involves the use of specialized polymerases with more flexible base-pairing 
properties which take over for the blocked replicative polymerase, permitting translesion 
synthesis (172).  Some mechanisms of translesion synthesis introduce mutations, but 
others do not.  For example, Pol η mediates error-free bypass of lesions induced by UV 
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irradiation, whereas Pol ζ introduces mutations at these sites (173).  The potential for 
introducing mutations during translesion synthesis may be less dangerous to the cell than 
completely arresting DNA synthesis or continuing the cell cycle with incompletely 
replicated DNA.   The studies presented here investigate the nature of the lesions induced 
by GCV as well as the involvement of DNA repair pathways in responding to this 
damage. 
 
Dissertation Research Rationale 
The overall aim of this dissertation was to (1) investigate and characterize novel 
interactions of GCV with DNA, including the induction of DNA damage and 
mechanisms of DNA repair following GCV exposure, and (2) to provide a molecular 
explanation of the mechanism(s) by which GCV is more cytotoxic than other HSV-TK 
substrates.  Although it had previously been determined that GCV induces cytotoxicity 
by incorporation into DNA and arrests cells in the second S phase following drug 
exposure, the nature of DNA damage induced had not been determined.  It was my 
hypothesis that incorporation of GCVMP into DNA would cause more severe DNA 
damage, such as stalled or collapsed replication forks, DNA breaks, or mutations, than 
other HSV-TK substrates.  Specific differences in DNA damage produced by GCV 
compared to other HSV-TK substrates have not been determined, and these differences 
will add to the understanding of GCV-mediated cell killing and may help to explain the 
superior cytotoxicity of GCV.   
Not only is the nature of the GCV-induced DNA damage poorly understood, little 
is known about DNA repair pathways involved in responding to this damage.  The only 
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report that provided evidence that GCVMP incorporated into DNA is subjected to repair 
implicated base excision repair because inhibition of DNA polymerase β sensitized cells 
to GCV (174).  To date, no other data have been published which propose other 
mechanisms of DNA repair involved in responding to GCV incorporation into DNA. 
Rubsam et al provided a direct comparison of the metabolism, DNA 
incorporation, and cell cycle effects of GCV and araT, but did not characterize the 
mechanism of the differing cell cycle progression induced by these agents (71).  Chapter 
II extends the finding that GCV induces cell death at the second attempt to traverse S-
phase by characterizing the extent and kinetics of DNA damage.  By comparing DNA 
damage induced by GCV to that observed with araT, it was determined that GCV induces 
more DNA damage than araT and this damage is induced in a biphasic pattern, with a 
secondary induction of DNA damage occurring with similar timing to the S phase arrest 
observed following GCV treatment.  The induction of Rad51 foci following GCV 
treatment further supported a role for homologous recombination in repairing GCV-
mediated DNA damage. 
The initial induction of DNA damage during GCV exposure decreased following 
drug removal, suggesting that repair had occurred.  Studies included in Chapter III 
evaluated DNA repair mechanisms involved in responding to GCV-induced DNA 
damage.  First, a role for mismatch repair was investigated.  Second, a yeast-based assay 
was utilized to screen a panel of DNA repair mutants for increased sensitivity to GCV.  
This assay confirmed the MMR repair results and further demonstrated a role for 
homologous recombination and cell cycle checkpoints in responding to GCV-mediated 
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DNA damage.  Similar experiments in mammalian cells would have taken considerably 
longer, and these results provide specific pathways to translate into human cells. 
In order to more thoroughly understand the effects of GCVMP incorporation into 
DNA, in Chapter IV we characterized specific DNA mutations induced following 
treatment with GCV compared to other HSV-TK substrates.  The presence of unique 
mutations in GCV-treated cells compared to control cells or those treated with other 
HSV-TK substrates suggests that the small changes in structures of these drugs results in 
dramatically different effects on the fidelity of DNA polymerases.  This translated into 
different effects on cell cycle progression by the different HSV-TK substrates and 
suggests different mechanisms of cell killing for each substrate.  
The research presented in this dissertation has provided the field with knowledge 
of GCV’s ability to induce DNA damage as well as repair pathways involved in 
responding to this damage, leading to increased understanding of the unique ability of 
GCV to cause multi-log cell killing.  Better understanding of this mechanism may lead to 
improvement of this gene therapy technique or to the development of new anti-cancer 





 (1)  Brady RC, Bernstein DI. Treatment of herpes simplex virus infections. Antiviral 
Res 2004; 61(2):73-81. 
 (2)  Weinberg JM. Herpes zoster: epidemiology, natural history, and common 
complications. J Am Acad Dermatol 2007; 57(6 Suppl):S130-S135. 
 (3)  Whitley RJ. Herpes simplex encephalitis: adolescents and adults. Antiviral Res 
2006; 71(2-3):141-148. 
 (4)  Chen MS, Walker J, Prusoff WH. Kinetic studies of herpes simplex virus type 1-
encoded thymidine and thymidylate kinase, a multifunctional enzyme. J Biol 
Chem 1979; 254(21):10747-10753. 
 (5)  Whitley R, Alford C, Hess F, Buchanan R. Vidarabine: a preliminary review of its 
pharmacological properties and therapeutic use. Drugs 1980; 20(4):267-282. 
 (6)  Whitley RJ. The past as prelude to the future: history, status, and future of 
antiviral drugs. Ann Pharmacother 1996; 30(9):967-971. 
 (7)  Keller PM, Fyfe JA, Beauchamp L, Lubbers CM, Furman PA, Schaeffer HJ et al. 
Enzymatic phosphorylation of acyclic nucleoside analogs and correlations with 
antiherpetic activities. Biochem Pharmacol 1981; 30(22):3071-3077. 
 (8)  Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. 
Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) 
guanine. Proc Natl Acad Sci U S A 1977; 74(12):5716-5720. 
 (9)  Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M et al. 
Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44 
Suppl 1:S1-26. 
 (10)  Cheng YC, Grill SP, Dutschman GE, Nakayama K, Bastow KF. Metabolism of 9-
(1,3-dihydroxy-2-propoxymethyl)guanine, a new anti-herpes virus compound, in 
herpes simplex virus-infected cells. J Biol Chem 1983; 258(20):12460-12464. 
 (11)  Hamzeh FM, Lietman PS. Intranuclear accumulation of subgenomic 
noninfectious human cytomegalovirus DNA in infected cells in the presence of 
ganciclovir. Antimicrob Agents Chemother 1991; 35(9):1818-1823. 
 (12)  Reardon JE, Spector T. Herpes simplex virus type 1 DNA polymerase. 
Mechanism of inhibition by acyclovir triphosphate. J Biol Chem 1989; 
264(13):7405-7411. 
 (13)  Field AK, Davies ME, DeWitt C, Perry HC, Liou R, Germershausen J et al. 9-([2-
hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes 
group virus replication. Proc Natl Acad Sci U S A 1983; 80(13):4139-4143. 
 21 
 (14)  Smee DF, Boehme R, Chernow M, Binko BP, Matthews TR. Intracellular 
metabolism and enzymatic phosphorylation of 9-(1,3-dihydroxy-2-
propoxymethyl)guanine and acyclovir in herpes simplex virus-infected and 
uninfected cells. Biochem Pharmacol 1985; 34(7):1049-1056. 
 (15)  Ashton WT, Karkas JD, Field AK, Tolman RL. Activation by thymidine kinase 
and potent antiherpetic activity of 2'-nor-2'-deoxyguanosine (2'NDG). Biochem 
Biophys Res Commun 1982; 108(4):1716-1721. 
 (16)  Boehme RE. Phosphorylation of the antiviral precursor 9-(1,3-dihydroxy-2-
propoxymethyl)guanine monophosphate by guanylate kinase isozymes. J Biol 
Chem 1984; 259(20):12346-12349. 
 (17)  Biron KK, Stanat SC, Sorrell JB, Fyfe JA, Keller PM, Lambe CU et al. Metabolic 
activation of the nucleoside analog 9-[( 2-hydroxy-1-
(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected 
with human cytomegalovirus. Proc Natl Acad Sci U S A 1985; 82(8):2473-2477. 
 (18)  Martin JC, Dvorak CA, Smee DF, Matthews TR, Verheyden JP. 9-[(1,3-
Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes 
agent. J Med Chem 1983; 26(5):759-761. 
 (19)  Smith KO, Galloway KS, Kennell WL, Ogilvie KK, Radatus BK. A new 
nucleoside analog, 9-[[2-hydroxy-1-(hydroxymethyl)ethoxyl]methyl]guanine, 
highly active in vitro against herpes simplex virus types 1 and 2. Antimicrob 
Agents Chemother 1982; 22(1):55-61. 
 (20)  Agut H, Collandre H, Aubin JT, Guetard D, Favier V, Ingrand D et al. In vitro 
sensitivity of human herpesvirus-6 to antiviral drugs. Res Virol 1989; 140(3):219-
228. 
 (21)  Agut H, Huraux JM, Collandre H, Montagnier L. Susceptibility of human 
herpesvirus 6 to acyclovir and ganciclovir. Lancet 1989; 2(8663):626. 
 (22)  Lin JC, Smith MC, Pagano JS. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-
propoxymethyl)guanine against replication of Epstein-Barr virus. J Virol 1984; 
50(1):50-55. 
 (23)  Cheng YC, Huang ES, Lin JC, Mar EC, Pagano JS, Dutschman GE et al. Unique 
spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against 
herpesviruses in vitro and its mode of action against herpes simplex virus type 1. 
Proc Natl Acad Sci U S A 1983; 80(9):2767-2770. 
 (24)  Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. 
Antimicrob Agents Chemother 2005; 49(3):873-883. 
 22 
 (25)  Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading 
frame encodes a protein that phosphorylates the antiviral nucleoside analogue 
ganciclovir. Nature 1992; 358(6382):160-162. 
 (26)  Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK. A protein 
kinase homologue controls phosphorylation of ganciclovir in human 
cytomegalovirus-infected cells. Nature 1992; 358(6382):162-164. 
 (27)  Plotkin SA, Starr SE, Bryan CK. In vitro and in vivo responses of 
cytomegalovirus to acyclovir. Am J Med 1982; 73(1A):257-261. 
 (28)  Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 
1998; 338(24):1741-1751. 
 (29)  Ljungman P. Beta-herpesvirus challenges in the transplant recipient. J Infect Dis 
2002; 186 Suppl 1:S99-S109. 
 (30)  Drew WL. Cytomegalovirus infection in patients with AIDS. J Infect Dis 1988; 
158(2):449-456. 
 (31)  Rubin RH. Prevention and treatment of cytomegalovirus disease in heart 
transplant patients. J Heart Lung Transplant 2000; 19(8):731-735. 
 (32)  Ho M. Advances in understanding cytomegalovirus infection after transplantation. 
Transplant Proc 1994; 26(5 Suppl 1):7-11. 
 (33)  Hodson EM, Jones CA, Webster AC, Strippoli GF, Barclay PG, Kable K et al. 
Antiviral medications to prevent cytomegalovirus disease and early death in 
recipients of solid-organ transplants: a systematic review of randomised 
controlled trials. Lancet 2005; 365(9477):2105-2115. 
 (34)  Snydman DR. Infection in solid organ transplantation. Transpl Infect Dis 1999; 
1(1):21-28. 
 (35)  Noble S, Faulds D. Ganciclovir. An update of its use in the prevention of 
cytomegalovirus infection and disease in transplant recipients. Drugs 1998; 
56(1):115-146. 
 (36)  Sugawara M, Huang W, Fei YJ, Leibach FH, Ganapathy V, Ganapathy ME. 
Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters 
PEPT1 and PEPT2. J Pharm Sci 2000; 89(6):781-789. 
 (37)  Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and 
CMV-seropositive subjects. J Clin Pharmacol 1999; 39(8):800-804. 
 (38)  Cocohoba JM, McNicholl IR. Valganciclovir: an advance in cytomegalovirus 
therapeutics. Ann Pharmacother 2002; 36(6):1075-1079. 
 23 
 (39)  Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB et al. 
Valganciclovir results in improved oral absorption of ganciclovir in liver 
transplant recipients. Antimicrob Agents Chemother 2000; 44(10):2811-2815. 
 (40)  Sommadossi JP, Bevan R. High-performance liquid chromatographic method for 
the determination of 9-(1,3-dihydroxy-2-propoxymethyl)guanine in human 
plasma. J Chromatogr 1987; 414(2):429-433. 
 (41)  Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity, 
pharmacokinetic properties and therapeutic efficacy in cytomegalovirus 
infections. Drugs 1990; 39(4):597-638. 
 (42)  Anderson RD, Griffy KG, Jung D, Dorr A, Hulse JD, Smith RB. Ganciclovir 
absolute bioavailability and steady-state pharmacokinetics after oral 
administration of two 3000-mg/d dosing regimens in human immunodeficiency 
virus- and cytomegalovirus-seropositive patients. Clin Ther 1995; 17(3):425-432. 
 (43)  Sommadossi JP, Carlisle R. Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-
dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor 
cells in vitro. Antimicrob Agents Chemother 1987; 31(3):452-454. 
 (44)  McGuffin RW, Shiota FM, Meyers JD. Lack of toxicity of acyclovir to 
granulocyte progenitor cells in vitro. Antimicrob Agents Chemother 1980; 
18(3):471-473. 
 (45)  Mickisch GH, Aksentijevich I, Schoenlein PV, Goldstein LJ, Galski H, Stahle C 
et al. Transplantation of bone marrow cells from transgenic mice expressing the 
human MDR1 gene results in long-term protection against the myelosuppressive 
effect of chemotherapy in mice. Blood 1992; 79(4):1087-1093. 
 (46)  Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A et al. 
Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of 
human MDR1. Science 1992; 257(5066):99-103. 
 (47)  Moritz T, Mackay W, Glassner BJ, Williams DA, Samson L. Retrovirus-mediated 
expression of a DNA repair protein in bone marrow protects hematopoietic cells 
from nitrosourea-induced toxicity in vitro and in vivo. Cancer Res 1995; 
55(12):2608-2614. 
 (48)  May C, Gunther R, McIvor RS. Protection of mice from lethal doses of 
methotrexate by transplantation with transgenic marrow expressing drug-resistant 
dihydrofolate reductase activity. Blood 1995; 86(6):2439-2448. 
 (49)  Spencer HT, Sleep SE, Rehg JE, Blakley RL, Sorrentino BP. A gene transfer 
strategy for making bone marrow cells resistant to trimetrexate. Blood 1996; 
87(6):2579-2587. 
 24 
 (50)  Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral 
vector-mediated gamma-interferon gene transfer into tumor cells generates potent 
and long lasting antitumor immunity. Cancer Res 1990; 50(24):7820-7825. 
 (51)  Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 
gene transfer into tumor cells abrogates tumorigenicity and induces protective 
immunity. J Exp Med 1990; 172(4):1217-1224. 
 (52)  Porgador A, Tzehoval E, Vadai E, Feldman M, Eisenbach L. Immunotherapy via 
gene therapy: comparison of the effects of tumor cells transduced with the 
interleukin-2, interleukin-6, or interferon-gamma genes. J Immunother Emphasis 
Tumor Immunol 1993; 14(3):191-201. 
 (53)  Porgador A, Bannerji R, Watanabe Y, Feldman M, Gilboa E, Eisenbach L. 
Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma 
gene-inserted tumor cells. J Immunol 1993; 150(4):1458-1470. 
 (54)  Porgador A, Gansbacher B, Bannerji R, Tzehoval E, Gilboa E, Feldman M et al. 
Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor 
cells. Int J Cancer 1993; 53(3):471-477. 
 (55)  Cai DW, Mukhopadhyay T, Liu Y, Fujiwara T, Roth JA. Stable expression of the 
wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene 
transfer. Hum Gene Ther 1993; 4(5):617-624. 
 (56)  Xu HJ, Zhou Y, Seigne J, Perng GS, Mixon M, Zhang C et al. Enhanced tumor 
suppressor gene therapy via replication-deficient adenovirus vectors expressing an 
N-terminal truncated retinoblastoma protein. Cancer Res 1996; 56(10):2245-
2249. 
 (57)  Georges RN, Mukhopadhyay T, Zhang Y, Yen N, Roth JA. Prevention of 
orthotopic human lung cancer growth by intratracheal instillation of a retroviral 
antisense K-ras construct. Cancer Res 1993; 53(8):1743-1746. 
 (58)  Zhang Y, Mukhopadhyay T, Donehower LA, Georges RN, Roth JA. Retroviral 
vector-mediated transduction of K-ras antisense RNA into human lung cancer 
cells inhibits expression of the malignant phenotype. Hum Gene Ther 1993; 
4(4):451-460. 
 (59)  Nishihara E, Nagayama Y, Narimatsu M, Namba H, Watanabe M, Niwa M et al. 
Treatment of thyroid carcinoma cells with four different suicide gene/prodrug 
combinations in vitro. Anticancer Res 1998; 18(3A):1521-1525. 
 (60)  Shirakawa T, Gardner TA, Ko SC, Bander N, Woo S, Gotoh A et al. Cytotoxicity 
of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is 
superior to thymidine kinase plus acyclovir in a human renal cell carcinoma 
model. J Urol 1999; 162(3 Pt 1):949-954. 
 25 
 (61)  Trinh QT, Austin EA, Murray DM, Knick VC, Huber BE. Enzyme/prodrug gene 
therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine 
kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell 
line. Cancer Res 1995; 55(21):4808-4812. 
 (62)  Martiniello-Wilks R, Garcia-Aragon J, Daja MM, Russell P, Both GW, Molloy 
PL et al. In vivo gene therapy for prostate cancer: preclinical evaluation of two 
different enzyme-directed prodrug therapy systems delivered by identical 
adenovirus vectors. Hum Gene Ther 1998; 9(11):1617-1626. 
 (63)  Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine 
kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 
1986; 46(10):5276-5281. 
 (64)  Moolten FL. An alternative to the magic bullet paradigm for specific cancer 
therapy. Med Hypotheses 1987; 24(1):43-51. 
 (65)  Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase 
genes transferred by retroviral vectors. J Natl Cancer Inst 1990; 82(4):297-300. 
 (66)  Moolten FL, Wells JM, Heyman RA, Evans RM. Lymphoma regression induced 
by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum Gene 
Ther 1990; 1(2):125-134. 
 (67)  Domin BA, Mahony WB, Zimmerman TP. Membrane permeation mechanisms of 
2',3'-dideoxynucleosides. Biochem Pharmacol 1993; 46(4):725-729. 
 (68)  Haberkorn U, Khazaie K, Morr I, Altmann A, Muller M, van Kaick G. 
Ganciclovir uptake in human mammary carcinoma cells expressing herpes 
simplex virus thymidine kinase. Nucl Med Biol 1998; 25(4):367-373. 
 (69)  Buursma AR, van Dillen IJ, van Waarde A, Vaalburg W, Hospers GA, Mulder 
NH et al. Monitoring HSVtk suicide gene therapy: the role of [(18)F]FHPG 
membrane transport. Br J Cancer 2004; 91(12):2079-2085. 
 (70)  Mahony WB, Domin BA, Zimmerman TP. Ganciclovir permeation of the human 
erythrocyte membrane. Biochem Pharmacol 1991; 41(2):263-271. 
 (71)  Rubsam LZ, Davidson BL, Shewach DS. Superior cytotoxicity with ganciclovir 
compared with acyclovir and 1-beta-D-arabinofuranosylthymine in herpes 
simplex virus-thymidine kinase-expressing cells: a novel paradigm for cell killing. 
Cancer Res 1998; 58(17):3873-3882. 
 (72)  Imaizumi K, Hasegawa Y, Kawabe T, Emi N, Saito H, Naruse K et al. Bystander 
tumoricidal effect and gap junctional communication in lung cancer cell lines. Am 
J Respir Cell Mol Biol 1998; 18(2):205-212. 
 26 
 (73)  Rubsam LZ, Boucher PD, Murphy PJ, KuKuruga M, Shewach DS. Cytotoxicity 
and accumulation of ganciclovir triphosphate in bystander cells cocultured with 
herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma 
cells. Cancer Res 1999; 59(3):669-675. 
 (74)  Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus-thymidine 
kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular 
communication. Cancer Res 2000; 60(15):3989-3999. 
 (75)  Boucher PD, Ostruszka LJ, Murphy PJ, Shewach DS. Hydroxyurea significantly 
enhances tumor growth delay in vivo with herpes simplex virus thymidine 
kinase/ganciclovir gene therapy. Gene Ther 2002; 9(15):1023-1030. 
 (76)  Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are 
we going? J Natl Cancer Inst 1997; 89(1):21-39. 
 (77)  Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten 
FL et al. The "bystander effect": tumor regression when a fraction of the tumor 
mass is genetically modified. Cancer Res 1993; 53(21):5274-5283. 
 (78)  Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic 
cooperation is responsible for the bystander effect observed with HSV tk 
retroviral gene therapy. Hum Gene Ther 1993; 4(6):725-731. 
 (79)  Mese G, Richard G, White TW. Gap junctions: basic structure and function. J 
Invest Dermatol 2007; 127(11):2516-2524. 
 (80)  Fick J, Barker FG, Dazin P, Westphale EM, Beyer EC, Israel MA. The extent of 
heterocellular communication mediated by gap junctions is predictive of 
bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci U S A 1995; 
92(24):11071-11075. 
 (81)  Pope IM, Poston GJ, Kinsella AR. The role of the bystander effect in suicide gene 
therapy. Eur J Cancer 1997; 33(7):1005-1016. 
 (82)  Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of 
cancer cells by herpes simplex virus thymidine kinase gene is mediated by 
connexins. Proc Natl Acad Sci U S A 1996; 93(5):1831-1835. 
 (83)  Mesnil M, Piccoli C, Yamasaki H. A tumor suppressor gene, Cx26, also mediates 
the bystander effect in HeLa cells. Cancer Res 1997; 57(14):2929-2932. 
 (84)  Vrionis FD, Wu JK, Qi P, Waltzman M, Cherington V, Spray DC. The bystander 
effect exerted by tumor cells expressing the herpes simplex virus thymidine 
kinase (HSVtk) gene is dependent on connexin expression and cell 
communication via gap junctions. Gene Ther 1997; 4(6):577-585. 
 27 
 (85)  Gentry BG, Im M, Boucher PD, Ruch RJ, Shewach DS. GCV phosphates are 
transferred between HeLa cells despite lack of bystander cytotoxicity. Gene Ther 
2005; 12(13):1033-1041. 
 (86)  Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV et al. 
MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral 
drugs. Nat Med 1999; 5(9):1048-1051. 
 (87)  Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F et al. 
Multidrug-resistance protein 5 is a multispecific organic anion transporter able to 
transport nucleotide analogs. Proc Natl Acad Sci U S A 2000; 97(13):7476-7481. 
 (88)  Fillat C, Carrio M, Cascante A, Sangro B. Suicide gene therapy mediated by the 
Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of 
application. Curr Gene Ther 2003; 3(1):13-26. 
 (89)  Maatta AM, Korja S, Venhoranta H, Hakkarainen T, Pirinen E, Heikkinen S et al. 
Transcriptional targeting of virus-mediated gene transfer by the human 
hexokinase II promoter. Int J Mol Med 2006; 18(5):901-908. 
 (90)  Konopka K, Overlid N, Nagaraj AC, Duzgunes N. Serum decreases the size of 
Metafectene-and Genejammer-DNA complexes but does not affect significantly 
their transfection activity in SCCVII murine squamous cell carcinoma cells. Cell 
Mol Biol Lett 2006; 11(2):171-190. 
 (91)  Serikawa T, Kikuchi A, Sugaya S, Suzuki N, Kikuchi H, Tanaka K. In vitro and 
in vivo evaluation of novel cationic liposomes utilized for cancer gene therapy. J 
Control Release 2006; 113(3):255-260. 
 (92)  Okada T, Caplen NJ, Ramsey WJ, Onodera M, Shimazaki K, Nomoto T et al. In 
situ generation of pseudotyped retroviral progeny by adenovirus-mediated 
transduction of tumor cells enhances the killing effect of HSV-tk suicide gene 
therapy in vitro and in vivo. J Gene Med 2004; 6(3):288-299. 
 (93)  Munir KM, French DC, Dube DK, Loeb LA. Herpes thymidine kinase mutants 
with altered catalytic efficiencies obtained by random sequence selection. Protein 
Eng 1994; 7(1):83-89. 
 (94)  Balzarini J, Bohman C, De Clercq E. Differential mechanism of cytostatic effect 
of (E)-5-(2-bromovinyl)-2'-deoxyuridine, 9-(1,3-dihydroxy-2-
propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected 
by the thymidine kinase gene of herpes simplex virus type 1 or type 2. J Biol 
Chem 1993; 268(9):6332-6337. 
 (95)  Black ME, Newcomb TG, Wilson HM, Loeb LA. Creation of drug-specific 
herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc Natl 
Acad Sci U S A 1996; 93(8):3525-3529. 
 28 
 (96)  Black ME, Kokoris MS, Sabo P. Herpes simplex virus-1 thymidine kinase 
mutants created by semi-random sequence mutagenesis improve prodrug-
mediated tumor cell killing. Cancer Res 2001; 61(7):3022-3026. 
 (97)  Kokoris MS, Sabo P, Adman ET, Black ME. Enhancement of tumor ablation by a 
selected HSV-1 thymidine kinase mutant. Gene Ther 1999; 6(8):1415-1426. 
 (98)  Qiao J, Black ME, Caruso M. Enhanced ganciclovir killing and bystander effect 
of human tumor cells transduced with a retroviral vector carrying a herpes 
simplex virus thymidine kinase gene mutant. Hum Gene Ther 2000; 11(11):1569-
1576. 
 (99)  Wiewrodt R, Amin K, Kiefer M, Jovanovic VP, Kapoor V, Force S et al. 
Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine 
kinase mutants improves prodrug-mediated tumor cell killing. Cancer Gene Ther 
2003; 10(5):353-364. 
 (100)  Pantuck AJ, Matherly J, Zisman A, Nguyen D, Berger F, Gambhir SS et al. 
Optimizing prostate cancer suicide gene therapy using herpes simplex virus 
thymidine kinase active site variants. Hum Gene Ther 2002; 13(7):777-789. 
 (101)  Chen SH, Chen XH, Wang Y, Kosai K, Finegold MJ, Rich SS et al. Combination 
gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci 
U S A 1995; 92(7):2577-2581. 
 (102)  Chen SH, Kosai K, Xu B, Pham-Nguyen K, Contant C, Finegold MJ et al. 
Combination suicide and cytokine gene therapy for hepatic metastases of colon 
carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res 
1996; 56(16):3758-3762. 
 (103)  O'Malley BW, Cope KA, Chen SH, Li D, Schwarta MR, Woo SL. Combination 
gene therapy for oral cancer in a murine model. Cancer Res 1996; 56(8):1737-
1741. 
 (104)  O'Malley BW, Jr., Sewell DA, Li D, Kosai K, Chen SH, Woo SL et al. The role 
of interleukin-2 in combination adenovirus gene therapy for head and neck 
cancer. Mol Endocrinol 1997; 11(6):667-673. 
 (105)  Majumdar AS, Zolotorev A, Samuel S, Tran K, Vertin B, Hall-Meier M et al. 
Efficacy of herpes simplex virus thymidine kinase in combination with cytokine 
gene therapy in an experimental metastatic breast cancer model. Cancer Gene 
Ther 2000; 7(7):1086-1099. 
 (106)  Caruso M, Pham-Nguyen K, Kwong YL, Xu B, Kosai KI, Finegold M et al. 
Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. 
Proc Natl Acad Sci U S A 1996; 93(21):11302-11306. 
 29 
 (107)  Toda M, Martuza RL, Rabkin SD. Combination suicide/cytokine gene therapy as 
adjuvants to a defective herpes simplex virus-based cancer vaccine. Gene Ther 
2001; 8(4):332-339. 
 (108)  Drozdzik M, Qian C, Xie X, Peng D, Bilbao R, Mazzolini G et al. Combined gene 
therapy with suicide gene and interleukin-12 is more efficient than therapy with 
one gene alone in a murine model of hepatocellular carcinoma. J Hepatol 2000; 
32(2):279-286. 
 (109)  Colombo F, Barzon L, Franchin E, Pacenti M, Pinna V, Danieli D et al. 
Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma 
multiforme: biological and clinical results. Cancer Gene Ther 2005; 12(10):835-
848. 
 (110)  Pasanen T, Karppinen A, Alhonen L, Janne J, Wahlfors J. Polyamine biosynthesis 
inhibition enhances HSV-1 thymidine kinase/ganciclovir-mediated cytotoxicity in 
tumor cells. Int J Cancer 2003; 104(3):380-388. 
 (111)  Wahlfors T, Karppinen A, Janne J, Alhonen L, Wahlfors J. Polyamine depletion 
and cell cycle manipulation in combination with HSV thymidine 
kinase/ganciclovir cancer gene therapy. Int J Oncol 2006; 28(6):1515-1522. 
 (112)  McMasters RA, Wilbert TN, Jones KE, Pitlyk K, Saylors RL, Moyer MP et al. 
Two-drug combinations that increase apoptosis and modulate bak and bcl-X(L) 
expression in human colon tumor cell lines transduced with herpes simplex virus 
thymidine kinase. Cancer Gene Ther 2000; 7(4):563-573. 
 (113)  Ilsley DD, Lee SH, Miller WH, Kuchta RD. Acyclic guanosine analogs inhibit 
DNA polymerases alpha, delta, and epsilon with very different potencies and have 
unique mechanisms of action. Biochemistry 1995; 34(8):2504-2510. 
 (114)  Rainov NG, Fels C, Droege JW, Schafer C, Kramm CM, Chou TC. 
Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir 
therapy of malignant glioma. Cancer Gene Ther 2001; 8(9):662-668. 
 (115)  Wildner O, Blaese RM, Morris JC. Synergy between the herpes simplex virus 
tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan. 
Hum Gene Ther 1999; 10(16):2679-2687. 
 (116)  Chase M, Chung RY, Chiocca EA. An oncolytic viral mutant that delivers the 
CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat 
Biotechnol 1998; 16(5):444-448. 
 (117)  Aghi M, Chou TC, Suling K, Breakefield XO, Chiocca EA. Multimodal cancer 
treatment mediated by a replicating oncolytic virus that delivers the 
oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus 
thymidine kinase gene therapies. Cancer Res 1999; 59(16):3861-3865. 
 30 
 (118)  Carrio M, Visa J, Cascante A, Estivill X, Fillat C. Intratumoral activation of 
cyclophosphamide by retroviral transfer of the cytochrome P450 2B1 in a 
pancreatic tumor model. Combination with the HSVtk/GCV system. J Gene Med 
2002; 4(2):141-149. 
 (119)  Boucher PD, Ostruszka LJ, Shewach DS. Synergistic enhancement of herpes 
simplex virus thymidine kinase/ganciclovir-mediated cytoxicity by hydroxyurea. 
Cancer Res 2000; 60(6):1631-1636. 
 (120)  Gentry BG, Boucher PD, Shewach DS. Hydroxyurea induces bystander 
cytotoxicity in cocultures of herpes simplex virus thymidine kinase-expressing 
and nonexpressing HeLa cells incubated with ganciclovir. Cancer Res 2006; 
66(7):3845-3851. 
 (121)  Boucher PD, Shewach DS. In Vitro and in Vivo Enhancement of Ganciclovir-
Mediated Bystander Cytotoxicity with Gemcitabine. Mol Ther 2005. 
 (122)  Wildner O, Blaese RM, Candotti F. Enzyme prodrug gene therapy: synergistic use 
of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and 
thymidylate synthase inhibitors for the treatment of colon cancer. Cancer Res 
1999; 59(20):5233-5238. 
 (123)  Rogulski KR, Kim JH, Kim SH, Freytag SO. Glioma cells transduced with an 
Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide 
and radiosensitivity. Hum Gene Ther 1997; 8(1):73-85. 
 (124)  Uckert W, Kammertons T, Haack K, Qin Z, Gebert J, Schendel DJ et al. Double 
suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but 
not single gene transfer allows reliable elimination of tumor cells in vivo. Hum 
Gene Ther 1998; 9(6):855-865. 
 (125)  Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged 
approach to kill cancer cells selectively: concomitant viral, double suicide gene, 
and radiotherapy. Hum Gene Ther 1998; 9(9):1323-1333. 
 (126)  Aghi M, Kramm CM, Chou TC, Breakefield XO, Chiocca EA. Synergistic 
anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine 
deaminase gene therapies. J Natl Cancer Inst 1998; 90(5):370-380. 
 (127)  Boucher PD, Im MM, Freytag SO, Shewach DS. A novel mechanism of 
synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide 
gene therapy. Cancer Res 2006; 66(6):3230-3237. 
 (128)  Rogulski KR, Zhang K, Kolozsvary A, Kim JH, Freytag SO. Pronounced 
antitumor effects and tumor radiosensitization of double suicide gene therapy. 
Clin Cancer Res 1997; 3(11):2081-2088. 
 31 
 (129)  Blackburn RV, Galoforo SS, Corry PM, Lee YJ. Adenoviral transduction of a 
cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells 
enhances prodrug and radiation sensitivity. Int J Cancer 1999; 82(2):293-297. 
 (130)  Klatzmann D, Valery CA, Bensimon G, Marro B, Boyer O, Mokhtari K et al. A 
phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene 
therapy for recurrent glioblastoma. Study Group on Gene Therapy for 
Glioblastoma. Hum Gene Ther 1998; 9(17):2595-2604. 
 (131)  Shand N, Weber F, Mariani L, Bernstein M, Gianella-Borradori A, Long Z et al. 
A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme 
by tumor transduction with the herpes simplex thymidine kinase gene followed by 
ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther 1999; 
10(14):2325-2335. 
 (132)  Sandmair AM, Loimas S, Puranen P, Immonen A, Kossila M, Puranen M et al. 
Thymidine kinase gene therapy for human malignant glioma, using replication-
deficient retroviruses or adenoviruses. Hum Gene Ther 2000; 11(16):2197-2205. 
 (133)  Trask TW, Trask RP, Aguilar-Cordova E, Shine HD, Wyde PR, Goodman JC et 
al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir 
administration in patients with current malignant brain tumors. Mol Ther 2000; 
1(2):195-203. 
 (134)  Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber K et al. 
Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene 
therapy in patients with localized malignancy: results of a phase I clinical trial in 
malignant mesothelioma. Hum Gene Ther 1998; 9(7):1083-1092. 
 (135)  Link CJ, Jr., Moorman D, Seregina T, Levy JP, Schabold KJ. A phase I trial of in 
vivo gene therapy with the herpes simplex thymidine kinase/ganciclovir system 
for the treatment of refractory or recurrent ovarian cancer. Hum Gene Ther 1996; 
7(9):1161-1179. 
 (136)  Alvarez RD, Gomez-Navarro J, Wang M, Barnes MN, Strong TV, Arani RB et al. 
Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther 2000; 
2(5):524-530. 
 (137)  Herman JR, Adler HL, Aguilar-Cordova E, Rojas-Martinez A, Woo S, Timme TL 
et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical 
trial. Hum Gene Ther 1999; 10(7):1239-1249. 
 (138)  Freytag SO, Khil M, Stricker H, Peabody J, Menon M, DePeralta-Venturina M et 
al. Phase I study of replication-competent adenovirus-mediated double suicide 
gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 
2002; 62(17):4968-4976. 
 32 
 (139)  Freytag SO, Stricker H, Pegg J, Paielli D, Pradhan DG, Peabody J et al. Phase I 
study of replication-competent adenovirus-mediated double-suicide gene therapy 
in combination with conventional-dose three-dimensional conformal radiation 
therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate 
cancer. Cancer Res 2003; 63(21):7497-7506. 
 (140)  Freytag SO, Stricker H, Movsas B, Kim JH. Prostate cancer gene therapy clinical 
trials. Mol Ther 2007; 15(6):1042-1052. 
 (141)  Freytag SO, Movsas B, Aref I, Stricker H, Peabody J, Pegg J et al. Phase I trial of 
replication-competent adenovirus-mediated suicide gene therapy combined with 
IMRT for prostate cancer. Mol Ther 2007; 15(5):1016-1023. 
 (142)  Freytag SO, Stricker H, Peabody J, Pegg J, Paielli D, Movsas B et al. Five-year 
Follow-up of Trial of Replication-competent Adenovirus-mediated Suicide Gene 
Therapy for Treatment of Prostate Cancer. Mol Ther 2007; 15(3):636-642. 
 (143)  Nasu Y, Saika T, Ebara S, Kusaka N, Kaku H, Abarzua F et al. Suicide gene 
therapy with adenoviral delivery of HSV-tK gene for patients with local 
recurrence of prostate cancer after hormonal therapy. Mol Ther 2007; 15(4):834-
840. 
 (144)  Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 
thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection 
and radiation in adults with previously untreated glioblastoma multiforme. Hum 
Gene Ther 2000; 11(17):2389-2401. 
 (145)  Long Z, Lu P, Grooms T, Mychkovsky I, Westley T, Fitzgerald T et al. Molecular 
evaluation of biopsy and autopsy specimens from patients receiving in vivo 
retroviral gene therapy. Hum Gene Ther 1999; 10(5):733-740. 
 (146)  Rogulski KR, Wing MS, Paielli DL, Gilbert JD, Kim JH, Freytag SO. Double 
suicide gene therapy augments the antitumor activity of a replication-competent 
lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum Gene 
Ther 2000; 11(1):67-76. 
 (147)  Freytag SO, Barton KN, Brown SL, Narra V, Zhang Y, Tyson D et al. 
Replication-competent adenovirus-mediated suicide gene therapy with radiation 
in a preclinical model of pancreatic cancer. Mol Ther 2007; 15(9):1600-1606. 
 (148)  Couriel D, Caldera H, Champlin R, Komanduri K. Acute graft-versus-host 
disease: pathophysiology, clinical manifestations, and management. Cancer 2004; 
101(9):1936-1946. 
 (149)  Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin 
Hematol 2006; 43(1):3-10. 
 33 
 (150)  Kornblau SM, Aycox PG, Stephens C, McCue LD, Champlin RE, Marini FC. 
Control of graft-versus-host disease with maintenance of the graft-versus-
leukemia effect in a murine allogeneic transplant model using retrovirally 
transduced murine suicidal lymphocytes. Exp Hematol 2007; 35(5):842-853. 
 (151)  Bondanza A, Valtolina V, Magnani Z, Ponzoni M, Fleischhauer K, Bonyhadi M 
et al. Suicide gene therapy of graft-versus-host disease induced by central 
memory human T lymphocytes. Blood 2006; 107(5):1828-1836. 
 (152)  Gendelman M, Yassai M, Tivol E, Krueger A, Gorski J, Drobyski WR. Selective 
elimination of alloreactive donor T cells attenuates graft-versus-host disease and 
enhances T-cell reconstitution. Biol Blood Marrow Transplant 2003; 9(12):742-
752. 
 (153)  Drobyski WR, Morse HC, III, Burns WH, Casper JT, Sandford G. Protection 
from lethal murine graft-versus-host disease without compromise of 
alloengraftment using transgenic donor T cells expressing a thymidine kinase 
suicide gene. Blood 2001; 97(8):2506-2513. 
 (154)  Kornblau SM, Stiouf I, Snell V, Przepiorka D, Stephens LC, Champlin R et al. 
Preemptive control of graft-versus-host disease in a murine allogeneic transplant 
model using retrovirally transduced murine suicidal lymphocytes. Cancer Res 
2001; 61(8):3355-3360. 
 (155)  Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L et al. HSV-
TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-
leukemia. Science 1997; 276(5319):1719-1724. 
 (156)  Tiberghien P, Ferrand C, Lioure B, Milpied N, Angonin R, Deconinck E et al. 
Administration of herpes simplex-thymidine kinase-expressing donor T cells with 
a T-cell-depleted allogeneic marrow graft. Blood 2001; 97(1):63-72. 
 (157)  Recchia A, Bonini C, Magnani Z, Urbinati F, Sartori D, Muraro S et al. Retroviral 
vector integration deregulates gene expression but has no consequence on the 
biology and function of transplanted T cells. Proc Natl Acad Sci U S A 2006; 
103(5):1457-1462. 
 (158)  Ciceri F, Bonini C, Marktel S, Zappone E, Servida P, Bernardi M et al. Antitumor 
effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell 
transplantation. Blood 2007; 109(11):4698-4707. 
 (159)  Traversari C, Marktel S, Magnani Z, Mangia P, Russo V, Ciceri F et al. The 
potential immunogenicity of the TK suicide gene does not prevent full clinical 
benefit associated with the use of TK-transduced donor lymphocytes in HSCT for 
hematologic malignancies. Blood 2007; 109(11):4708-4715. 
 34 
 (160)  Bonini C, Bondanza A, Perna SK, Kaneko S, Traversari C, Ciceri F et al. The 
suicide gene therapy challenge: how to improve a successful gene therapy 
approach. Mol Ther 2007; 15(7):1248-1252. 
 (161)  Thust R, Schacke M, Wutzler P. Cytogenetic genotoxicity of antiherpes 
virostatics in Chinese hamster V79-E cells. I. Purine nucleoside analogues. 
Antiviral Res 1996; 31(1-2):105-113. 
 (162)  Helleday T. Pathways for mitotic homologous recombination in mammalian cells. 
Mutat Res 2003; 532(1-2):103-115. 
 (163)  Sonoda E, Sasaki MS, Morrison C, Yamaguchi-Iwai Y, Takata M, Takeda S. 
Sister chromatid exchanges are mediated by homologous recombination in 
vertebrate cells. Mol Cell Biol 1999; 19(7):5166-5169. 
 (164)  Wilson DM, III, Thompson LH. Molecular mechanisms of sister-chromatid 
exchange. Mutat Res 2007; 616(1-2):11-23. 
 (165)  Halloran PJ, Fenton RG. Irreversible G2-M arrest and cytoskeletal reorganization 
induced by cytotoxic nucleoside analogues. Cancer Res 1998; 58(17):3855-3865. 
 (166)  Tomicic MT, Thust R, Kaina B. Ganciclovir-induced apoptosis in HSV-1 
thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2 decline and 
caspase-9 activation. Oncogene 2002; 21(14):2141-2153. 
 (167)  Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR 
kinases. Genes Dev 2001; 15(17):2177-2196. 
 (168)  Cline SD, Hanawalt PC. Who's on first in the cellular response to DNA damage? 
Nat Rev Mol Cell Biol 2003; 4(5):361-372. 
 (169)  West SC. Molecular views of recombination proteins and their control. Nat Rev 
Mol Cell Biol 2003; 4(6):435-445. 
 (170)  Helleday T, Lo J, van Gent DC, Engelward BP. DNA double-strand break repair: 
from mechanistic understanding to cancer treatment. DNA Repair (Amst) 2007; 
6(7):923-935. 
 (171)  Lieber MR, Ma Y, Pannicke U, Schwarz K. Mechanism and regulation of human 
non-homologous DNA end-joining. Nat Rev Mol Cell Biol 2003; 4(9):712-720. 
 (172)  Friedberg EC. Suffering in silence: the tolerance of DNA damage. Nat Rev Mol 
Cell Biol 2005; 6(12):943-953. 
 (173)  Kozmin SG, Pavlov YI, Kunkel TA, Sage E. Roles of Saccharomyces cerevisiae 
DNA polymerases Poleta and Polzeta in response to irradiation by simulated 
sunlight. Nucleic Acids Res 2003; 31(15):4541-4552. 
 35 
 (174)  Tomicic MT, Thust R, Sobol RW, Kaina B. DNA polymerase beta mediates 
protection of mammalian cells against ganciclovir-induced cytotoxicity and DNA 








DELAYED INDUCTION OF CELL DEATH BY GANCICLOVIR IS 




 Transfer of the herpes simplex virus thymidine kinase (HSV-TK) suicide gene to 
malignant cells followed by treatment with ganciclovir (GCV) is one of the most widely 
used strategies for cancer gene therapy.  Previously we demonstrated that GCV induced 
>3-logs more cell kill than HSV-TK substrates acyclovir and 1-β-D-arabinofuranosyl 
thymine (araT).  GCV exhibited a delayed mode of action, in which cells traversed the 
first S-phase and completed cell division after GCV exposure, but arrested during the 
second S-phase.  We have extended these studies by examining the role of DNA damage 
as a possible mechanism for the superior cytotoxicity of GCV.  Using γ-H2AX foci 
formation as an indicator of DNA damage, GCV induced at least 7-fold more foci than 
that observed with araT at equitoxic concentrations.  Although the number of foci 
decreased after removal of either drug suggesting repair of these early lesions, only GCV 
produced a late and persistent increase in foci indicating the induction of irreparable 
DNA damage.  Furthermore, only the late induction of γ-H2AX was associated with 
formation of Rad51 foci, implicating homologous recombination repair in cytotoxicity 
with GCV. The appearance of these late lesions corresponded to the timing of the second 
S-phase arrest.  These data demonstrate that GCV induces late DNA damage. The 
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Engineering tumor cells to express the herpes simplex virus type 1 thymidine 
kinase (HSV-TK) allows for the selective phosphorylation of ganciclovir (GCV) in 
transgene-expressing cells.  Further phosphorylation by cellular kinases results in the 
accumulation of the toxic metabolite, GCV 5'-triphosphate (GCVTP), which competes 
with dGTP for incorporation into DNA (1).  This approach has been successful in 
producing multi-log cell killing in vitro and strong tumor growth inhibition with some 
complete tumor regressions in animal models (2-6).  These results have prompted clinical 
trials in patients with a variety of malignancies, including brain tumors, and a 
combination therapy approach in prostate cancer.  Studies have demonstrated that HSV-
TK/GCV therapy is well tolerated, with promising antitumor activity in prostate cancer 
(7-9). 
Although the excellent cytotoxicity of HSV-TK/GCV has been documented in 
many different cell types, the mechanism by which cell death is induced is still not well 
understood.  Similar to other nucleoside analogs, the primary mechanism of cytotoxicity 
is due to the incorporation of GCV monophosphate (GCVMP) into DNA, where the 
analog is readily incorporated into internucleotide linkages (10,11).  While GCV shares 
this basic mechanism of cytotoxicity with other HSV-TK substrates, including acyclovir 
(ACV) and 1-β-D-arabinofuranosylthymine (araT), GCV induces multi-log cell killing at 
sub-micromolar concentrations, whereas ACV and araT are weakly cytotoxic at 
 38 
concentrations >100 µM (10).   Furthermore, treatment of cells with 0.1 µM GCV 
produced low GCVTP levels, similar to that of its endogenous competitor dGTP, yet this 
resulted in killing of 75% of the cells; however, accumulation of araT triphosphate was 
approximately 30 times higher and resulted in no significant cytotoxicity (IC10) after 
treatment with 1 µM araT.  At concentrations of 10 or 100 µM, accumulation of ACV 
triphosphate was 7-30 fold lower than GCVTP or araT triphosphate and incorporation of 
ACV monophosphate into DNA, where it acts as an obligate chain terminator (12,13), 
was below the limit of detection (10).  These data suggest that the low cytotoxicity with 
ACV was most likely due to poor incorporation of ACV phosphates into DNA.   
However, there is not a clear explanation for the superior cytotoxicity of GCV compared 
to araT despite its much lower incorporation into DNA. 
A few studies have attempted to address the mechanism by which GCV causes 
cell death.  A study in B16 murine melanoma cells indicated GCV induced a 
morphological change in cells due to the reorganization of components of the 
cytoskeleton as well as an accumulation of cells in G2/M after a 48-72 hr incubation (14).  
It has also been reported that GCV treatment results in a decline in Bcl-2 levels and 
activation of caspases, leading to apoptosis (15).  While these studies highlight pathways 
utilized by GCV that lead to cell death, this does not address the mechanism by which 
GCV is many logs more cytotoxic than other HSV-TK substrates.  However, one study 
demonstrated that GCV induced sister chromatid exchanges and chromosome breaks and 
translocations, whereas ACV did not (16,17).  Since sister chromatid exchanges arise as a 
consequence of homologous recombination repair (HRR) (18), these results suggest that 
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DNA damage and pathways involved in its repair differ significantly between these 
drugs.  
In a comparison of the events that lead to cytotoxicity for GCV and araT, we have 
reported a unique manner of delayed cell death in response to GCV (10).  Cells were able 
to complete one cell division cycle after incubation with GCV.  However, when they 
attempted to progress through the cell cycle for a second time, they were blocked in S 
phase where they remained until they underwent cell death.  In contrast, cells treated with 
araT accumulated in S phase and growth was inhibited for at least two days after drug 
removal, but subsequently cells progressed through the cell cycle and cell number 
increased.  This suggests that an event occurring during the second round of DNA 
replication following GCV treatment caused cells to arrest in S phase, resulting in cell 
death.  We have proposed that, during the second round of DNA replication, the presence 
of GCVMP in the template produces DNA damage that cannot be repaired, resulting in a 
persistent lesion.   
Taken together, these results suggest that GCV induces greater DNA damage with 
unique kinetics that results in multi-log cytotoxicity.  In an effort to understand the 
differences in cytotoxicity between GCV and other HSV-TK substrates, we wished to 
measure the extent and time course of DNA damage induction by GCV.  It has been 
reported previously that DNA damage results in the phosphorylation of histone H2AX on 
serine 139 by kinases such as Ataxia-telangiectasia mutated (ATM), ATM- and Rad3-
related (ATR), and DNA-dependent protein kinase (19-22).  Accumulation of 
phosphorylated H2AX (γ-H2AX) at the sites of DNA damage induced by radiation and 
drugs results in formation of discrete foci which can be visualized using a phospho-
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specific antibody (19,23-26).  γ-H2AX was originally thought to be a marker of DNA 
double strand breaks (DSBs), but has also been shown to be phosphorylated as a result of 
DNA polymerase and ribonucleotide reductase inhibition by aphidicolin and 
hydroxyurea, respectively, suggesting formation of γ-H2AX foci at sites of stalled 
replication (27,28).  Here we have characterized the formation of γ-H2AX foci following 
GCV treatment as a measure of DNA damage. 
Reports of sister chromatid exchanges induced by GCV suggest a role for HRR, a 
process involved in the repair of DSBs and stalled replication forks (29).  In order to 
characterize the involvement of this repair pathway, we measured the formation of foci 
containing Rad51, an essential protein mediating HRR (30).  We have utilized these 
techniques to compare the kinetics and extent of DNA damage with GCV and araT in 
order to elucidate the differences that might result in the superior cytotoxicity observed 
with GCV.   
 
Materials and Methods 
Cell Culture.  U251 human glioblastoma cell line was maintained in RPMI 1640 
medium supplemented with 10% calf serum (GIBCO, Grand Island, NY) and L-
glutamine (Fisher Scientific, Pittsburgh, PA).  Cells were maintained in exponential 
growth in a humidified atmosphere at 37ºC and 5% CO2.   U251 cells were transduced 
with a retroviral vector encoding the herpes simplex virus type 1 thymidine kinase along 
with the neomycin resistance gene.  Transgene expressing cells were selected with G418 
and individual colonies were expanded and maintained in medium containing G418.  
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HSV-TK tranduction was confirmed by assaying lysates for phosphorylated GCV 
metabolites.   
 
Analysis of γ-H2AX foci formation by laser scanning confocal microscopy.  
Exponentially growing U251 cells on 8-well coverslips were incubated with drug as 
indicated, washed with PBS and then fixed and permeabilized with acetone/methanol 
(50:50 v/v) for 10 min.  The fixed cells were then washed with PBS, blocked with 10% 
goat serum for 1 h, incubated with γ-H2AX primary antibody (1:400 dilution; Upstate, 
Charlottesville, VA) for 1 h, washed, incubated with AlexaFluor 488 conjugated goat 
anti-rabbit secondary antibody (1:200 dilution; Molecular Probes, Eugene, OR) for 1 h, 
washed and mounted with ProLong antifade kit (Molecular Probes, Eugene, OR).  Slides 
were imaged with a Zeiss LSM510 confocal microscope using a 60x objective lens.  
Images of representative cell populations were captured, and γ-H2AX foci were counted 
visually. 
 
Analysis of Rad51 foci formation by laser scanning confocal microscopy.  Drug was 
added to exponentially growing U251 cells on 8-well coverslips for 24 hours unless 
otherwise noted.  At specified timepoints, cells were washed with PBS and permeabilized 
with Triton-X buffer (0.5% Triton, 20mM Hepes, 50mM NaCl, 3mM KCl, 300mM 
Sucrose) for 5 min.  Permeabilized cells were then fixed with paraformaldehyde solution 
(3% PFA, 2% sucrose, 1X PBS) for 30 min, washed 3 times for 10 minutes in wash 
buffer (0.5% NP40, 0.3% Sodium Azide, 1X PBS), blocked with 10% goat serum for 1 
hour, and incubated with rabbit anti-Rad51 primary antibody (1:1600 dilution; 
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Calbiochem, La Jolla, CA) for 1.5 hours.  Cells were then washed 3 times in wash buffer, 
incubated with AlexaFluor 488 conjugated goat anti-rabbit secondary antibody (1:2000 
dilution; Molecular Probes, Eugene, OR) for 1 hour, washed 3 times in wash buffer then 
washed with DAPI (.1µg/ml DAPI in 1X PBS) and mounted with ProLong antifade kit 
(Molecular Probes, Eugene, OR).  Slides were imaged with an Olympus FV500 confocal 
microscope using a 100x objective lens.  Images of representative cell populations were 
captured, and Rad51 positive cells were scored visually (cells with 10+ foci were 
considered positive). 
 
Analysis of γ-H2AX and BrdUrd immunostaining by laser scanning confocal 
microscopy.  Exponentially growing U251 cells on 8-well coverslips were incubated 
with drug as indicated, followed by addition of 30 µM BrdUrd for 30 minutes at the 
conclusion of drug incubation.  Cells were fixed, permeabilized, and stained for γ-H2AX 
as described above, using AlexaFluor 594 conjugated goat anti-rabbit secondary 
antibody.  After the final wash, antibody complexes were fixed with 3.7% 
paraformaldehyde in PBS for 10 minutes.  Cells were treated with 2.5 N HCl for 30 
minutes at 37°C and stained with AlexaFluor 488 mouse anti-BrdUrd conjugate (1:20 
dilution, BD Pharmingen, San Jose, CA) for 1 hr.  Slides were mounted and imaged as 
described above.    
 
Analysis of γ-H2AX expression by flow cytometry.  After drug incubation, cells were 
harvested by trypsinization and washed with PBS.  The pellets were resuspended in ice-
cold PBS followed by the addition of cold 2% paraformaldehyde.  Samples were then 
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incubated at 4ºC for a minimum of 30 min.  Fixed samples were centrifuged and the 
pellets were resuspended in PBS containing 0.5% Tween 20 and incubated at 3ºC for 15 
min. PBS containing 0.5% Tween 20 and 5% serum (PBT) was added followed by 
centrifugation.  Pellets were then resuspended in PBT.  Anti-γ-H2AX antibody was added 
to each sample and incubated for 45 min at room temperature and then washed with PBT.  
The pellets were then resuspended in anti-rabbit phycoerythrin conjugate antibody 
(Sigma Chemical Co, St. Louis, MO) and incubated for 45 min at room temperature.  
Samples were washed with PBT and resuspended in 7-Amino Actinomycin D (7-AAD) 
(Molecular Probes, Eugene OR) and incubated at room temperature for at least 30 min 
prior to flow cytometric analysis. 
 
Results 
In order to evaluate DNA damage induced by GCV, U251tk cells were incubated 
with GCV for 24 hr and then assayed for γ-H2AX foci formation.   A dose-dependent 
increase in γ-H2AX foci was observed in cells treated with GCV compared to control 
cells (Figure 2.1A and B).  In the absence of drug, control cells contained an average of 
3.6 ± 2.5 γ-H2AX foci per cell.  Treatment with the IC10 (0.03 µM) for GCV resulted in a 
4.4-fold increase in γ-H2AX foci which was not significantly different from control (p = 
0.3).  Treatment with the IC50 (0.05 µM) and IC90 (0.3 µM) for GCV significantly 
increased the number of γ-H2AX foci per cell (14.3 + 6.4 fold and 24.4 ± 6.8 fold, 
respectively; p<0.001). 
 γ-H2AX expression was then assayed by flow cytometry in order to evaluate the 

































Figure 2.1. GCV induces a dose-dependent increase in γ-H2AX.  U251tk cells were 
incubated with GCV for 24 hr and assayed for γ-H2AX foci formation.  (A) 
representative cells as captured by confocal microscopy; (B) quantitation of the number 
γ-H2AX foci per cell. Columns, average of at least three separate experiments each 
consisting of at least 18 cells per condition; bars, SE. 




control cells, only 2% of the cells expressed detectable levels of γ-H2AX.  Treatment 
with 0.2 and 1 µM GCV for 24 hr significantly increased the percentage of cells 
expressing γ-H2AX to 20% (p<0.01) and 59% (p<0.001), respectively (Figures 2.2A and 
B).  Thus, two different independent methods have demonstrated an increase in γ-H2AX 
fluorescence with increasing GCV concentration.  Since we were interested in 
quantifying the number of sites of DNA damage per cell rather than just the percentage of 
cells positive for γ-H2AX, subsequent experiments measured DNA damage using the in 
situ assay. 
Since DNA damage can be induced in cells but may be repaired, we wished to 
determine the kinetics of γ-H2AX foci formation during drug incubation and their 
persistence after drug washout. U251tk cells were treated with either non-toxic (IC10) or 
cytotoxic (IC50, IC90) concentrations of GCV for 24 hr and assayed for γ-H2AX foci 
formation (Figure 2.3).   At each concentration of GCV tested, an increase in foci was 
apparent within 12 hr after drug addition which continued through the end of the 
incubation, but the number of foci decreased by 12 hr after drug washout.  At the IC10 for 
GCV, the number of foci remained similar to control levels throughout the 48 hr post-
washout period.  In contrast, between 24 and 48 hr after washout of GCV at the IC50 or 
IC90, the number of foci increased to greater than 10-fold over control.  
Since cells treated with GCV arrest permanently during the second round of DNA 
replication following drug incubation (10), we have proposed that a lesion or other type 
of damage in DNA is encountered leading to cell death.  Therefore we wished to 
determine if the presence of DNA damage, indicated by γ-H2AX foci, predominated in S 


























Figure 2.2. GCV induces a dose-dependent increase in γ-H2AX expression.  U251tk 
cells were incubated with GCV for 24 hr and assayed for γ-H2AX expression by flow 
cytometry; (A) cytogram illustrating separation of control and GCV-treated cells by γ-
H2AX fluorescence and (B) quantitation of percentage of γ-H2AX expressing cells from 
flow cytometry.  Points, mean of triplicate experiments; bars, standard error.
Control 
GCV 



















































Figure 2.3. Time course of γ-H2AX foci formation in response to GCV. U251tk cells 
were incubated with GCV at the indicated concentrations (IC10=0.03 µM, IC50=0.05 µM, 
IC90=0.3µΜ) for 24 h followed by drug washout. Cells were assayed by confocal 
microscopy for γ-H2AX foci formation at the indicated time points.  Black bar indicates 
duration of drug incubation, points represent the mean of at least three experiments each 





for 24 hr, then incubated with 5-bromo-2'-deoxyuridine (BrdUrd) briefly followed by 
staining for both the thymidine analog in DNA and γ-H2AX. At drug washout, the 
majority of γ-H2AX positive cells were in S phase, as indicated by BrdUrd incorporation, 
with a decrease to approximately one-third of γ-H2AX positive cells in S-phase by 24 hr 
after GCV washout (Table 2.1).  At 48 hr after IC50 washout, more than 80% of γ-H2AX 
labeled cells were in S-phase.  At 48 hr following washout of the IC90 for GCV, no cells 
stained positive for BrdUrd incorporation.  However, these cells exhibited massive cell 
death, with few intact cells remaining on the plate.  A separate study using dual 
parameter flow cytometry to detect DNA content with propidium iodide and DNA 
replication with BrdUrd incorporation confirmed that, at 48 hr after GCV washout, the 
majority of cells were in S phase but had low levels of BrdUrd incorporation due to 
decreased DNA synthesis (data not shown).   
In order to determine whether the amount of DNA damage could explain 
differences in cytotoxicity between GCV and araT, the induction of γ-H2AX foci by araT 
was evaluated.  After incubation of U251tk cells with the IC10, IC50, and IC80 for araT (1 
µM, 11 µM, and 100 µM, respectively) for 24 hr, a dose-dependent increase in γ-H2AX 
foci was observed (Figure 2.4A and B).  However, the magnitude of the increase in foci 
formation was considerably less with araT (2 - 3.5-fold increase compared to control) 
relative to GCV (15 - 25-fold increase, Figure 2.1B). 
Since γ-H2AX foci formation exhibited a biphasic pattern after GCV treatment, 
we evaluated the kinetics of foci formation with araT.  During a 24 hr incubation with 11 












% of γ-H2AX 
Positive cells that 
were BrdU Positive 
O h C 40 23 34 
 IC10 56 56 63 
 IC50 65 76 80 
 IC90 79 96 80 
      
24 h C 38 15 31 
 IC10 60 12 33 
 IC50 59 21 33 
 IC90 55 73 45 
      
48 h C n.d. n.d. n.d. 
 IC10 37 9 33 
 IC50 64 69 81 
  IC90 0 90 0 
 
 
Table 2.1. γ-H2AX expression and BrdUrd incorporation in response to GCV. 
U251tk cells were incubated with GCV at the indicated concentrations (IC10=0.03 µM, 
IC50=0.05 µM, IC90=0.3 µΜ) for 24 h followed by drug washout.  Cells were assayed for 
γ-H2AX foci formation and bromodeoxyuridine (BrdUrd) staining at the indicated time 
points.  Time = 0 represents the time of drug removal.  Values represent the percentage of 
cells that stained positive for γ-H2AX (contained greater than 5 foci), BrdUrd, or both.  





























Figure 2.4. araT induces a dose-dependent increase in γ-H2AX.  U251tk cells were 
incubated with araT for 24 hr and assayed for γ-H2AX foci formation.  (A) representative 
cells as captured by confocal microscopy; (B) quantitation of the number γ-H2AX foci 










approximately 2.25-fold greater than control.  The number of foci decreased by 12 hr 
after drug washout and remained slightly higher (approximately 1.7-fold) compared to 
control cells.  In contrast to the results with GCV, no further increase was observed for up 
to 96 hr after washout (Figure 2.5).      
The kinetics of γ-H2AX foci formation observed with cytotoxic concentrations of 
GCV suggested that the drug-induced DNA damage was initially repaired, but the 
secondary onset of damage was not repaired (Figure 2.3).  Since cytotoxic concentrations 
of GCV induce S-phase accumulation and a slowing of DNA replication, we wished to 
determine whether HRR was induced, since this is the primary repair pathway for DNA 
DSBs during S-phase (31,32).  Cells were treated with IC90 GCV and assayed for 
formation of foci containing Rad51 at the indicated time points.  Rad51 foci have been 
demonstrated to accumulate at sites of HRR and thus can be used as an indicator of this 
repair pathway following DNA damage (33).  At 12 h after drug addition and 0 and 12 h 
after drug washout, there was a small increase (approximately 2-fold) in Rad51 positive 
cells compared to untreated controls.  At 24 h after drug washout, the percentage of cells 
expressing Rad51 foci exhibited a large increase to 6-fold greater than control.  The 
percentage of Rad51 positive cells decreased thereafter, and at 72 h after drug washout 
the percentage of Rad51 positive cells returned to a 2-fold increase over control cells 
(Figure 2.6).  These data indicate that HRR was involved in repair of DNA damage 




























Figure 2.5. Time course of γ-H2AX foci formation in response to araT.  U251tk cells 
were incubated with 11µM araT (IC50) for 24 hr followed by drug washout.  Cells were 
assayed for γ-H2AX foci formation by confocal microscopy at the indicated time points 
and the number of γ-H2AX foci per cell was determined.  Black bar indicates duration of 






Figure 2.6 Time course of Rad51 foci formation in response to GCV.  U251tk cells 
were incubated with 0.3 µM GCV (IC90) for 24 h followed by drug washout. Cells were 
assayed by confocal microscopy for Rad51 (>10 Rad51 foci per cell) at the indicated time 
points.  Black bar, duration of drug incubation; points, mean of at least three wells from 
representative experiments; bars, standard error of the mean. 






























Most nucleoside analogues elicit cytotoxicity through incorporation into DNA (34-36).  
However, the extent of cell killing can differ between these drugs even though their 
primary mechanism of cytotoxicity is incorporation of the nucleotide analog into DNA.  
We have demonstrated previously that GCV was more cytotoxic than araT, despite the 
fact that U251 cells incorporated at least 5-fold more araTMP than GCVMP into DNA, 
suggesting that the functional consequences of incorporation induced by these nucleoside 
analogues is different (10).  Here we have measured DNA damage induced by GCV and 
araT using γ-H2AX foci formation, which demonstrated that GCV induced significantly 
more DNA damage than araT at equitoxic concentrations.  The biphasic kinetics of DNA 
damage observed uniquely with GCV likely reflect the role of HRR in a late but failed 
attempt at DNA repair, leading to multi-log cytotoxicity. 
Previous studies have demonstrated that treatment of cells with ionizing radiation 
or cytotoxic drugs induces γ-H2AX foci formation in a dose-dependent fashion (23,37-
39). It has also been reported that γ-H2AX foci are formed at stalled replication forks and 
do not solely represent DNA double strand breaks (40-42).  Additionally, non-cytotoxic 
concentrations of the DNA polymerase inhibitor aphidicolin induced H2AX 
phosphorylation (28).  In the data presented here, we have used two different methods to 
demonstrate that induction of γ-H2AX increased with increasing concentrations of GCV.  
Following drug washout, the number of γ-H2AX foci decreased demonstrating that the 
cells were able to repair a portion of this damage.  The γ-H2AX foci present during drug 
incubation may also indicate replication fork stalling, and γ-H2AX diminishes after drug 
is removed and replication resumes.  Time dependent resolution of foci formation has 
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been demonstrated by others using ionizing radiation (25,37).  However, we also 
observed a subsequent increase in γ-H2AX foci formation more than 24 hr after GCV 
washout, which to our knowledge has not been reported previously with other DNA 
damaging agents.  This late increase in foci occurred only at the two cytotoxic 
concentrations of GCV (IC50 and IC90), suggesting that this represents the lethal insult.  
Although the number of foci did not reach as high a level as observed during drug 
incubation, loss of cells due to cell death at this point interfered with our ability to 
quantify foci.  Co-staining for γ-H2AX and BrdUrd demonstrated that most of the γ-
H2AX foci were in S-phase cells at drug washout.  Furthermore, the late increase in γ-
H2AX foci at 48 hr after drug washout also was also associated primarily with cells in S-
phase, suggesting that the lethal insult occurred during attempted replication or repair of 
DNA. While many studies have focused on determining DNA damage during drug 
incubation, the studies presented here indicate that the critical events leading to cell death 
may occur long after drug washout. 
Following exposure of cells to araT, γ-H2AX foci formation was significantly 
different from that observed with GCV.  While there was a dose-dependent increase in 
foci formation with araT, the maximum number of foci was at least 7-fold lower with 
araT despite the fact  that more araTMP was incorporated into DNA (10).  This indicates 
that it is not simply the absolute amount of nucleotide analog incorporated into DNA but 
the consequences of that incorporation that is important for cytotoxicity.  Furthermore, 
the kinetics of foci formation and resolution was different from that observed with GCV.  
While the number of foci increased during incubation for both drugs, following araT 
washout foci formation decreased, whereas with GCV the number of foci increased by 36 
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hr post washout.  We have reported previously that apoptosis was induced similarly with 
both drugs, thus the increase in γ-H2AX foci following GCV treatment cannot be 
attributed to apoptosis (10).   
Previous reports demonstrate that GCV induces sister chromatid exchanges, 
suggesting a role for HRR in responding to GCV-induced DNA damage (16,43).   We 
further investigated HRR by analyzing Rad51 foci formation following treatment with 
GCV.   Unlike the pattern of γ-H2AX foci formation, only a 2-fold increase in Rad51 was 
observed during drug incubation while a single peak of cells with Rad51 foci was noted 
at 24 hr after drug washout.  This suggests that the DNA damage signaled by the initial 
peak of γ-H2AX during drug incubation did not utilize HRR for repair. As the percentage 
of Rad51 positive cells declined, a second increase in γ-H2AX foci formation was 
evident.  This suggests that, at 24 hr after GCV washout, cells are attempting to repair 
GCV-induced DNA damage through HRR.  However, the subsequent increase in γ-
H2AX suggests that HRR is not successful but rather it creates more DNA damage which 
does not appear to be repaired.  This increase in irreparable DNA damage leads to cell 
cycle arrest in the second S phase post-GCV exposure, resulting in cell death.  
The separable kinetics of γ-H2AX and Rad51 foci formation to our knowledge 
have not been reported before.  Typically cells are stained for γ-H2AX or Rad51 at one or 
two time points after radiation or drug addition, whereas here we performed a time-
dependent study over 96 hr.  At any given time, both γ-H2AX and Rad51 foci could be 
observed, however they achieved their peak of presentation 24 hr apart.  While γ-H2AX 
has been implicated in the formation of Rad51 foci (44), the 24 hr difference between the 
peak of γ-H2AX and Rad51 foci would argue against these events being associated.  
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Furthermore, cells progressed through the cell cycle and divided following drug washout, 
providing additional evidence that the initial γ-H2AX increase was not the signal for 
Rad51 foci formation. 
 In a previous report we demonstrated that, after treatment with GCV, cells were 
able to progress through one cell division cycle following drug removal and return to a 
normal cell cycle distribution.  However, as cells attempted to progress through S-phase 
for a second time at approximately 48 hr after GCV washout, they arrested permanently 
followed by cell death.  The results presented here support the cell cycle data.  The 
decrease in number of γ-H2AX foci to control levels and increase in Rad51 foci at 12-24 
hr following GCV washout occurred with similar timing to the return to a normal cell 
cycle distribution after drug treatment previously reported (10).  Indeed our BrdUrd data 
confirm that control levels of S-phase cells are present at 24 hr post-washout for the IC10 
and IC50 GCV.  The subsequent increase in γ-H2AX foci occurred with similar timing to 
the cells’ fatal attempt to progress through S-phase for the second time, as indicated by 
the increase in γ-H2AX/BrdUrd positive cells at 48 hr.  This suggests that late-occurring 
DNA damage that the cell cannot repair is important for GCV cytotoxicity.   
 We suggest that this damage may be the result of GCVMP in the template strand 
during DNA synthesis.  When DNA replication machinery encounters GCVMP in the 
template strand, the DNA polymerase may stall. This stalled replication fork may be 
sufficient for γ-H2AX induction and Rad51 foci may indicate HRR involvement in 
restarting the stalled replication fork.  Alternatively, it has been proposed that a stalled 
replication fork may result in recognition of a specific endonuclease which generates a 
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nick in the template, resulting in the formation of a DSB, thus resulting in H2AX 
phosphorylation and induction of HRR for DSB repair (Figure 2.7 and (29,45)).    
In summary, the patterns of γ-H2AX and Rad51 foci formation indicate that late-
occurring DNA damage, unable to be repaired by HRR, resulted in cell death with GCV.   
Furthermore, at equitoxic concentrations DNA damage was less severe with araT and did 
not persist, whereas GCV induced greater DNA damage and it occurred in biphasic 
fashion.  Although we do not know the nature of the persistent lesion with GCV, we 
suggest that DNA damage, possibly induced by attempted replication with GCVMP in 
the template, was unable to be repaired leading to cell death.  In contrast, we suggest that 
most of the DNA damage induced by araT was repaired, and cell effects other than direct 
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Figure 2.7. Proposed mechanism(s) of γ-H2AX and Rad51 foci formation in 
response to GCV.  When DNA replication machinery encounters GCVMP (▲)in the 
template strand during DNA synthesis, the DNA polymerase is stalled (1).  This stalled 
replication fork may be sufficient for γ-H2AX induction and Rad51 foci may indicate 
HRR involvement in restarting the stalled replication fork.  Alternatively, the stalled 
replication fork may result in recognition of a specific endonuclease which generates a 
nick in the template (2), resulting in the formation of a DSB, thus resulting in H2AX 
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EVALUATION OF DNA DAMAGE RESPONSE PATHWAYS IN SENSITIVITY 
TO GANCICLOVIR: MLH1 DEFICIENCY ENHANCES TUMOR CELL 





Suicide gene therapy with herpes simplex virus thymidine kinase and ganciclovir 
is notable for producing multi-log cytotoxicity in a unique pattern of delayed cytotoxicity 
in S-phase.  Because hydroxyurea, a ribonucleotide reductase inhibitor that activates 
mismatch repair, can increase sensitivity to ganciclovir, we evaluated the role of MLH1, 
an essential mismatch repair protein, in ganciclovir cytotoxicity.  Using isogenic 
HCT116TK (HSV-TK-expressing) colon carcinoma cells that express or lack MLH1, cell 
survival studies demonstrated greater ganciclovir sensitivity in the MLH1 deficient cells, 
primarily at high concentrations.   This could not be explained by differences in 
ganciclovir metabolism, as the less sensitive MLH1-expresssing cells accumulated more 
ganciclovir triphosphate and incorporated more into DNA.  Suppression of MLH1 in 
U251 glioblastoma or SW480 colon carcinoma cells also enhanced sensitivity to high 
concentrations of ganciclovir.  Studies in yeast confirmed the results with MLH1, and 
further suggested a role for homologous recombination repair and several cell cycle 
checkpoint proteins in ganciclovir cytotoxicity.   These data suggest that MLH1 can 
prevent cytotoxicity with ganciclovir, and enhancement of ganciclovir sensitivity with 
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hydroxyurea is likely due to increased incorporation of ganciclovir triphosphate into 
DNA and not activation of MLH1.   
 
Introduction 
In an effort to improve the selectivity of cancer chemotherapy, several suicide 
gene therapy strategies have been developed in which expression of a foreign gene in 
tumor cells activates a normally innocuous substrate to a cytotoxic metabolite (1).  One 
of the most widely investigated strategies employs transfer of the cDNA for the herpes 
simplex virus thymidine kinase (HSV-TK), and expression of the enzyme facilitates 
phosphorylation of the antiviral drug ganciclovir (GCV) to its 5'-monophosphate, 
GCVMP.  After subsequent phosphorylation by endogenous kinases to its 5'-triphosphate 
(GCVTP), this metabolite competes with dGTP for incorporation into DNA which leads 
to cell death (1).  This approach has been successful in producing multi-log cell killing in 
vitro and strong tumor growth inhibition with some complete tumor regressions in animal 
models (2-5).  These results have prompted clinical trials in patients with a variety of 
malignancies, and a combination therapy approach in prostate cancer.  Clinical studies 
have demonstrated that HSV-TK/GCV therapy is well tolerated (6-8), with promising 
antitumor activity as part of a multimodality approach in prostate cancer (9).    
HSV-TK/GCV is notable for its ability to cause high cytotoxicity through a 
unique manner of delayed cell death distinct from other antimetabolites.  Previously we 
demonstrated that GCV induced >3-logs more cell kill than other HSV-TK substrates, 
such as 1-β-D-arabinofuranosyl thymine (araT), despite the fact that more araT was 
incorporated into DNA than GCV (10).  U251 glioblastoma cells were able to complete 
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one cell division cycle after incubation with GCV for 24 hr.  However, when they 
attempted to progress through the cell cycle for a second time, they were blocked in S 
phase where they remained until they died.  In contrast, cells treated with araT 
accumulated in S phase and growth was inhibited for at least two days after drug 
removal, but subsequently surviving cells progressed through the cell cycle and cell 
number increased.  This suggests that, with GCV treatment, an event occurring during 
this second round of DNA replication caused cells to arrest in S phase, resulting in cell 
death.  Other reports demonstrated that, during a 48 – 72 hr continuous incubation in B16 
murine melanoma cells, GCV induced a morphological change in cells due to the 
reorganization of components of the cytoskeleton (11) and an accumulation of cells in S 
or G2/M (12).  In addition, GCV commonly induces an apoptotic cell death due to either 
a decline in Bcl-2 levels and activation of caspases (13,14),  or through a CD95-
dependent pathway (15).  
While these studies have documented changes in cell cycle progression and 
induction of apoptosis induced by GCV, the mechanism by which drug incorporation into 
DNA leads to these consequences is not known.  Based on our previous data 
demonstrating that treatment with GCV arrested cells in S phase, we hypothesized that 
attempted repair of GCV in the template leads to cell death.  Tomicic et al have 
implicated base excision repair in removal of GCVMP from DNA in CHO cells (16). 
Previously we reported that GCV cytotoxicity can be enhanced by the addition of 
hydroxyurea (HU), a ribonucleotide reductase inhibitor that produces an imbalance in 
dNTP pools, resulting in additive cytotoxicity in HSV-TK-expressing cells and 
synergistic cytotoxicity in non-HSV-TK-expressing bystander cells across a wide variety 
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of solid tumor cell lines (17-19).  Because HU causes an imbalance in dNTP pools which 
would lead to misincorporations and activation of the mismatch repair pathway (MMR) 
(20-22), this study aimed first to determine if MMR affects sensitivity to GCV.  Further 
experiments in a yeast-based system investigated the role of MMR and other DNA repair 
pathways in GCV cytotoxicity, highlighting additional pathways which may be involved 
in sensing or repairing GCV-mediated DNA damage. 
 
Materials and Methods 
Cell Culture.  HCT116 and SW480 human colon carcinoma and U251 human 
glioblastoma cell lines were maintained in Dulbecco’s Modified Eagle medium, 
McCoy’s, and RPMI (Invitrogen Life Technologies, Grand Island, NY); respectively.  
Media was supplemented with 2 mM L-glutamine (Fisher Scientific, Pittsburgh, PA) for 
all cell lines and 10% fetal bovine serum (Invitrogen) for HCT116 and SW480 and 10% 
bovine serum for U251 cells. All cells were maintained in exponential growth and kept in 
an atmosphere of 37°C and 5%CO2. 
 
Stable Gene-Expressing Cell Lines.  HCT116 0-1, HCT116 1-2, SW480, and U251 cell 
lines were transduced with a retroviral vector encoding the herpes simplex virus type 1 
thymidine kinase along with the neomycin resistance gene (4).  Transgene expressing 
cells were selected with G418 and individual colonies were expanded and maintained in 
media containing G418 (Invitrogen).  HSV-TK expression was confirmed by assaying 
lysates for phosphorylated GCV metabolites and immunoblotting for HSV-TK protein. 
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Clonogenic Cell Survival Assays.  Exponentially growing cells were treated with GCV 
(Cytovene, Syntex, Palo Alto, CA) for 24 hr, trypsinized and diluted to approximately 
100 viable cells per well in 6-well culture dishes.  After 10-14 days, the cell colonies 
were fixed in methanol:acetic acid (3:1), stained with 0.4% crystal violet (Fisher 
Scientific), and visually counted.  Cell survival is expressed as a fraction of the plating 
efficiency of control, non-drug treated cells.  Each data point was plated in triplicate, and 
all assays were performed at least twice.   
 
Cellular Nucleotide Analysis.  After incubation with [8-3H]GCV (Moravek 
Biochemicals, Inc., Brea, CA), cells were harvested by trypsinization and extracted with 
0.4 N perchloric acid and neutralized following drug exposure.   The acid-insoluble 
pellets containing radiolabled DNA were washed with 0.4 N perchloric acid and 
solubilized overnight in 1 N KOH.  Incorporation of [8-3H]GCV into DNA was 
quantitated by liquid scintillation spectrometry.  For analysis of cellular GCV 
triphosphate, fractions containing [8-3H]GCV triphosphate were collected and quantitated 
by liquid scintillation spectrometry based on the known specific activity of [8-3H]GCV. 
 
Depletion of MLH1 with small interfering RNA.  Cells were plated on 6 well plates at 
a density of 1.0 x 105 cells/ml and incubated for 24 hours.   Cells were transfected with 
100 nM siRNA directed to MLH1 or non-specific siRNA (Dharmacon, Lafayette, CO) 
and Lipofectamine 2000 (Invitrogen, Grand Island, NY).  At 24 hours post-transfection, 
media was replaced.  Cells were expanded at 48 hours post-transfection and incubated for 
an additional 48 hours.  Drug was added for 24 hours, and clonogenic cell survival assays 
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were performed.  Cell lysates were collected at time of drug addition for Western Blot 
analysis of hMLH1 levels.   
 
Immunoblot analysis.  Whole-cell lysates were prepared in buffer [0.5 M Tris-HCl, 1.5 
M NaCl, 2.5% deoxycholic acid, 10% NP40, 10 mM EDTA (pH 7.4)], with the addition 
of protease inhibitors (Complete Mini Protease Inhibitor Cocktail tablet, Roche, 
Indianapolis, IN).  Proteins were separated by SDS-PAGE on 10% acrylamide gels and 
transferred onto Immobilon-P  membrane (Millipore Corp., Bedford, MA). Blots were 
probed with hMLH1 polyclonal rabbit (Santa Cruz Biotechnology, Santa Cruz, CA) or 
HSV-TK polyclonal rabbit antibodies and anti-rabbit horseradish peroxidase–linked 
antibodies. Proteins were visualized using an enhanced chemiluminescence detection 
system (Pierce, Rockford, IL). 
 
Saccharomyces cerevisiae strains and expression constructs.  The base yeast strain 
used in these experiments, YW929 (MATα, ade2::STE3-MET15, his3∆1, leu2∆0, 
met15∆0, ura3∆0), was derived from the previously described suicide deletion strain 
YW798 by allowing the latter to undergo chromosome breakage and repair and selecting 
an ade2 mutant product clone (23).  HSV-TK and deoxycytidine kinase (dCK) expression 
constructs were created by amplifying the corresponding coding sequences with tailed 
primers so that the products could be ligated as a Bam HI-Sal I fragment into the 
previously described expression vector pTW300 (24).  The product plasmids pTW382 
and pTW383 express dCK and HSV-TK, respectively, from the strong constitutive ADH1 
promoter with a Myc epitope and His6 tag fused to the amino terminus. Chromosomal 
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expression constructs were then made by amplifying the ADH1-Myc-His6-dCK/HSV-TK 
cassettes by PCR using primers with tails homologous to the yeast CAN1 gene.  The 
fragments were transformed into YW929, canavanine-resistant can1 colonies identified, 
and correct integration verified by PCR, α-Myc Western blot, and demonstration of drug-
specific toxicity.  The resulting yeast strains were YW967 (YW929 can1∆::ADH1-dCK) 
and YW968 (YW929 can1∆::ADH1-TK).  Primer sequences are available on request.   
 Introduction of yeast gene deletion mutations was accomplished by a previously 
described mating strategy (25).  Briefly, YW968 was mated in array format to a 
previously described single-plate array of 96 DNA damage response gene deletion 
mutants (25).  Following selection of diploids and sporulation, recombinant haploids of 
the genotype MATα, ade2::STE3-MET15, can1∆::ADH1-TK, his3∆1, leu2∆0, met15∆0, 
ura3∆0, xxx∆::kanMX4 (where xxx refers to the various deleted genes) were identified 
by their growth as red (i.e. ade2) colonies on plates selective for methionine and 
containing canavanine and G418.   
 
Measurement of GCV sensitivity in Saccharomyces cerevisiae.  Overnight cultures 
were diluted 50-fold in synthetically defined media with glucose as the carbon source 
(24) and allowed to grow for 5 hr shaking at 280 rpm at 30° C. Cultures were then diluted 
to a calculated OD600 = 0.0005 in the same media containing varying concentrations of 
GCV.  Growth was continued until the OD600 of the untreated control reached 0.5 ± 0.15 
(~10 doublings).  The OD600 of all cultures was then determined.  Values are expressed as 
a fraction of the optical density of the corresponding untreated control sample.  
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Complementation of mutant Saccharomyces cerevisiae strains.  PCR primers were 
designed to amplify the gene of interest (coding sequence plus 1000 bp upstream of the 
start codon) from wild-type yeast genomic DNA.  Primers included tail regions (forward:  
5'-TGGCGGCCGCTCTAGAACTAGTGGATCCCC, reverse: 5'-GATAAGCTTGATAT 
CGAATTCCTGCAGCCC) to allow gap repair of Sma I-digested vector pRS316 (URA3, 
CEN/ARS).  Digested plasmid and PCR products were co-transformed into yeast strains 
containing the corresponding gene deletions to generate recombinant plasmids.  Colonies 
were picked and tested for sensitivity to GCV as described above.  
  
Results 
These studies utilized the HCT116 0-1 cells, which are MMR deficient due to a 
truncated essential protein for MMR (MLH1) (26), and HCT116 1-2 cells which stably 
express MLH1 from its full length cDNA and are MMR proficient.  Stably expressing 
HSV-TK clonal sublines were generated for both the MMR-deficient HCT116 0-1 and 
the MMR-proficient HCT116 1-2 cell lines.   As illustrated in Figure 3.1, both of the 
HCT116 0-1tk clones (MMR deficient) were more sensitive to GCV than any of the 
HCT116 1-2tk clones (MMR proficient), especially at high GCV concentrations.  One 
clonal subline from each cell line was chosen based on similar growth rates and 
sensitivity to GCV.   Cytotoxicity of GCV in these two clonal sublines was similar at 
concentrations of 1 µM or less (% control survival at 1 µM = 3 ± 0.5% and 5.2 ± 1.4%, 
respectively); however, at 10 µM GCV, greater than one log more cell kill was observed 
in the MMR-deficient 0-1tk cells compared to the MMR-proficient 1-2tk cells (percent 







Figure 3.1. Sensitivity of HSV-TK-expressing HCT116 cells to GCV.  Exponentially 
growing HCT116 0-1 (dashed line) and 1-2 cells (solid line) stably expressing HSV-TK 
were exposed to increasing concentrations of GCV for 24 hours. Clonogenic cell survival 
was determined and expressed as a fraction of plating efficiency for untreated cells. 
Points represent a mean of triplicate samples, bars represent standard error.  Cell lines 























To determine whether the difference in cytotoxicity could be explained by 
differential metabolism of GCV in the two cell lines, we measured accumulation of 
GCVTP and its incorporation into DNA.  In both cell lines, there was an increase in 
GCVTP during drug incubation, and a subsequent decrease in GCVTP levels following 
drug washout (Figure 3.2A).  The HCT116 1-2tk clone accumulated approximately 3 
times more GCVTP than the HCT116 0-1tk clone following treatment with 1 µM GCV 
(55.9 ± 3.9 pmol GCVTP/106 cells and 17.8 ± 1.4 pmol GCVTP/106 cells, respectively).  
There was an increase in the amount of GCVTP incorporated into DNA during drug 
incubation and for 6 to 8 hours following drug removal.  The HCT116 1-2tk cells 
incorporated approximately two-fold more GCVMP into DNA than the 0-1tk cells (5.3 ± 
0.3 pmol GCVMP/106 cells, 2.4 ± 0.01 pmol GCVMP/106 cells, respectively), consistent 
with the higher pool of GCVTP (Figure 3.2B). GCVMP was well-retained in DNA in 
both sublines for at least 48 hr after drug washout.  The slight decrease detected in 
HCT116 0-1tk cells was accounted for by an increase in cell number (data not shown).  
Interestingly, 1 µM GCV was equitoxic in these two clones, despite the fact that there 
was twice as much GCVMP in the DNA of the 1-2tk clone.  Similar results were 
obtained at 10 µM GCV in which the HCT116 1-2tk cells accumulated up to 4 times 
more GCVTP and up to 2 times more GCVMP in DNA compared to the HCT116 0-1tk 
cells (data not shown). Western blot analysis demonstrated that HCT116 1-2tk clone 
expressed substantially more HSV-TK than the HCT116 0-1tk clone, which accounts for 
the higher GCVTP accumulation and GCVMP incorporation into DNA observed in the 
HCT116 1-2tk clone (Figure 3.2C).  Thus, reduced metabolism does not appear to 








Figure 3.2 Metabolism of GCV in HCT116tk cell lines. (A) Accumulation of 
[3H]GCVTP and (B) incorporation of [3H]GCVMP into DNA were determined in 
HCT116 0-1tk (dashed line) and HCT116 1-2tk (solid line) treated with GCV for 24 
hours.  Points represent the mean of at least triplicate samples, bars represent SEM. (C) 
Whole cell lysates were analyzed by Western blotting for HSV-TK expression.  
Expression of actin was used as a loading control.   















































Incubation Hr after GCV washout 
Drug 
Incubation Hr after GCV washout 
 75 
Because differential expression of HSV-TK in the two clones resulted in different 
levels of GCVTP, the cytotoxicity of GCV was tested in the parental (non-HSV-TK 
expressing) HCT116 cell lines.  If cells that do not express HSV-TK are treated with high 
concentrations of GCV, the drug can be phosphorylated by cellular enzymes (27), and we 
assumed that this phosphorylation would be equivalent in the parental cell lines.  Similar 
to the results in the HSV-TK-expressing cells, the MMR-deficient HCT116 0-1 cell line 
was more sensitive to GCV than the MMR-proficient HCT116 1-2 cell line (IC50 = 120 ± 
5.8 µM and 477 ± 23.3 µM, respectively; p=0.0001) (Figure 3.3), with >1-log difference 
in survival at GCV concentrations >300 µM, suggesting that the higher sensitivity of the 
HSV-TK-expressing HCT116 0-1 cells was due to MMR deficiency.   
Because MMR deficiency produces a mutator phenotype which may have 
affected sensitivity to GCV in the HCT116 0-1 cells,  siRNA was used to suppress MLH1 
expression in two other cell lines, U251tk human glioblastoma and SW480tk human 
colon carcinoma, both of which stably expressed HSV-TK and are considered MMR 
proficient (28).  MLH1 decreased substantially by 72 hr post-siRNA transfection and 
remained suppressed for at least another 48 hr in both cell lines (Figures 3.4A and 3.5A).    
Suppression of MLH1 expression by siRNA increased the sensitivity of both cell lines to 
GCV, primarily at highly cytotoxic drug concentrations (>90% cell killing) (Figures 3.4B 
and 3.5B).  Although there was not a complete deficiency of MLH1 in these studies, 
sensitivity to GCV was increased significantly, observed by a decrease in the IC99 for 
GCV from 6.25 ± 0.92 µM to 1.66 ± 0.11 µM in SW480tk (p = 0.02) and from 1.59 ± 









Figure 3.3. Sensitivity of non-HSV HCT116 cells to GCV.  Exponentially growing 
HCT116 0-1 (dashed line) and 1-2 cells (solid line) non-HSV-TK expressing cells were 
exposed to increasing concentrations of GCV for 24 hours.  Clonogenic cell survival was 
determined and expressed as a fraction of plating efficiency for untreated cells. Points 
represent a mean of triplicate samples, bars represent standard error. 
























Figure 3.4.  Depletion of MLH1 results in increased sensitivity to GCV in SW480tk 
cells. (A)Whole cell lysates were analyzed by Western blotting for MLH1 expression 
following no treatment (C), transfection with non-specific siRNA (NS) or MLH1 siRNA.  
Expression of actin was used as a loading control.   (B) Sensitivity of cells treated with 
siRNA directed to MLH1 (dashed line), non-specific (NS) siRNA (solid line with 
triangles), or no siRNA (solid line with squares) was determined following exposure to 
increasing concentrations of GCV.  Points represent the mean of triplicate experiments, 
bars represent SEM. 





























   
Figure 3.5.  Depletion of MLH1 results in increased sensitivity to GCV in U251tk 
cells.  (A) Whole cell lysates were analyzed by Western blotting for MLH1 expression 
following siRNA transfection.  Expression of actin was used as a loading control.   (B) 
Sensitivity of cells treated with siRNA directed to MLH1 (dashed line), non-specific 
siRNA (solid line with triangles), or no siRNA (solid line with squares) was determined 
following exposure to increasing concentrations of GCV.  Points represent the mean of 
triplicate experiments, bars represent SEM. 

























In order to evaluate other DNA repair pathways that participate in repair of GCV-
induced lesions, a Saccharomyces cerevisiae-based genetic screen was utilized to 
discover DNA damage response mutants with increased sensitivity to GCV.  HSV-TK 
was placed under control of the strong constitutive yeast ADH1 promoter and integrated 
into yeast chromosome V to stably express the gene.  GCV conferred dose-dependent 
toxicity only in HSV-TK-expressing yeast and not in control yeast or those expressing 
deoxycytidine kinase (dCK) (Figure 3.6).  Note that higher concentrations of GCV were 
required to affect growth of HSV-TK-expressing yeast compared to mammalian cells, 
which is typical in yeast likely due to poor transport properties for many drugs (29) and 
the high capacity of yeast for DNA repair, especially homologous recombination repair 
(30).  
 HSV-TK expression was next introduced into a panel of 96 DNA damage 
response yeast deletion mutants and the resulting strains screened for sensitivity to GCV.  
Table 3.1 indicates that MMR mutants exhibited a low to moderate increase in sensitivity 
to GCV at the concentrations tested.  Mutants deficient in the MMR genes MLH1 or 
MSH2 were as sensitive as controls at a moderate concentration of GCV (0.3 mM) but 
exhibited significantly increased sensitivity at 5 mM (% control density = 62.4 ± 1.9 for 
the WT-HSV-TK strain and 46.2 ± 1.1 (p<0.01) and  50.1 ± 4.0  (p<0.05) for mlh1 and 
msh2 yeast, respectively).  Yeast with deletions in homologous recombination repair or 
cell cycle checkpoint genes exhibited high sensitivity to GCV.  Deletion mutants for the 
endonucleases MUS81 or MMS4 also showed high sensitivity to GCV, which may be 
due to their putative role in HRR (31).  In addition, the increased sensitivity of the asf1 
mutant may be due to its role as a histone chaperone protein which may implicate it 
 80 
 
Figure 3.6.  HSV-TK expression sensitizes S. cerevisiae to GCV.  Exponentially 
growing liquid cultures of S. cerevisiae strains expressing HSV-TK, dCK, or no 
exogenous enzyme were treated with increasing concentrations of GCV.  Cell density 
was determined and expressed as a fraction of the density of untreated control cultures.  





















RecQ/Topo III TOP3 ++
SGS1 +++
helicase HPR5 ++
MRX complex RAD50 +++































































Table 3.1. Sensitivity of yeast strains to ganciclovir: +++, increase in sensitivity to 0.3 
mM GCV (≤50% control density); ++, increase in sensitivity to 5 mM GCV (≤25% 
control density); +, modest increase in sensitivity to 5 mM GCV (≤50% control density); 
and - indicates no difference from control.  The results were first determined by analysis 
of the array in 96 well plates and validated in triplicate in 2 ml liquid cultures. 
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in HRR or other DNA repair pathways (32).   
In order to verify that the deleted genes were in fact responsible for the increased 
sensitivity to GCV, representative mutant strains (RecQ helicase, sgs1; MRX subunit 
involved in double strand break repair, rad50; homologous recombination protein, rad52; 
checkpoint protein, dun1; and 9-1-1 complex member, rad17) with moderate to high 
GCV sensitivity were complemented with the corresponding wild-type gene in a plasmid.  
In all cases, complementation resulted in decreased sensitivity to GCV, similar to wild-
type levels (Figure 3.7A-E) as expected, thus verifying that the gene deletion was 
responsible for the increased drug sensitivity.   
 
Discussion 
Previously we have demonstrated a strong S-phase block associated with GCV 
cytotoxicity, suggesting that GCV produced irreparable DNA damage (10).  However, 
the type of damage and the repair pathways that may be involved in repairing GCV-
induced DNA damage have not been identified.  Here we have evaluated the role of 
MLH1, a protein required for MMR, in the cytotoxicity of GCV using several human cell 
lines of varying sensitivity to GCV.  Additional pathways that may be involved in GCV 
cytotoxicity were identified using a yeast deletion mutant assay.  The results demonstrate 
that, at high concentrations of GCV, human or yeast cells that express MLH1 are less 
sensitive to GCV induced cytotoxicity.  The yeast assay also implicated HRR in GCV 
cytotoxicity.  These results suggest that GCV induces specific lesions that can be repaired 
by MMR or HRR, and impairment of these pathways leads to increased cytotoxicity. 
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Figure 3.7. Complementation of S. cerevisiae mutants restores resistance to GCV.  
Exponentially growing liquid cultures of S. cerevisiae strains expressing HSV-TK and 
bearing specific gene deletion mutations [(a) sgs2, (b) rad50, (c) rad52, (d) dun1, (e) 
rad17] and their complemented counterparts were treated with increasing concentrations 
of GCV and cell density determined as in Figure 3.6. Solid lines and squares indicate 
wild-type yeast, dotted lines with open triangles indicate specific deletion mutants, and 
dashed and dotted lines with closed triangles indicate complemented strains.  Points 
represent the mean of triplicate experiments, bars represent SEM. 
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The increase in cytotoxicity in HCT116 0-1 cells (deficient in MLH1) compared 
to HCT116 1-2 cells (expressing MLH1) was not due to an increase in GCVTP or its 
incorporation into DNA, since the HCT116 1-2 cells actually accumulated more GCVMP 
in the DNA than those deficient in MLH1.  Further evidence for a direct role of MLH1 in 
cytotoxicity of GCV was demonstrated by the results in the U251 and SW480 cells using 
MLH1-specific siRNA, as well as the yeast assay which all demonstrated increased 
cytotoxicity of GCV in cells deficient in MLH1, primarily at high drug 
concentrations. Using siRNA to suppress MLH1 was important because it controlled for 
any differences the matched HCT116 cell lines may have accumulated, after many years 
of being cultured separately, that could affect GCV sensitivity.  While the siRNA did not 
result in a complete reduction of MLH1, these cells still displayed an increase in 
sensitivity to GCV.  Furthermore, the siRNA studies demonstrated that two different cell 
lines which differed in inherent sensitivity to GCV both exhibited increased sensitivity at 
>IC90 for GCV when MLH1 expression was decreased.   
There are several possibilities for the mechanism by which MLH1 deficiency 
enhances GCV cytotoxicity.  Differential incorporation into DNA did not explain the 
decreased sensitivity of MMR proficient (MLH1 expressing) cells to GCV, raising the 
possibility that MLH1 is not recognizing or responding to the presence of GCVMP but 
rather other lesions in the DNA.  MLH1 is a required protein for MMR, and therefore if 
high concentrations of GCV induce errors during DNA replication, such as mismatched 
nucleotides, deficiency of MLH1 would lead to more errors which may enhance 
cytotoxicity.  Currently we are evaluating the possibility that GCV induces replication 
errors either during incorporation or as a result of GCVMP in the template during DNA 
 85 
synthesis.  Alternatively, MLH1 may protect cells from GCV-induced damage through 
downstream signaling, since MLH1 is known to participate in a variety of other pathways 
such as base excision repair, cell cycle checkpoints, and apoptosis (33-35).      
Previously we have demonstrated that HU enhances cell killing with GCV (17-
19), and we suggested that this occurred through the increased incorporation of GCVTP 
into DNA due to the HU-mediated decrease in dGTP.  Alternatively, since HU-mediated 
dNTP pool imbalances activate MMR, it was also possible that HU enhanced cytotoxicity 
of GCV through activation of MMR which might increase incorporation of GCVMP into 
DNA as HU-induced mismatches were repaired, as suggested previously for the 
increased sensitivity of gemcitabine in MMR-proficient cells (36).  However, direct 
evaluation in MMR-proficient and deficient cell lines here demonstrated that deletion or 
suppression of the required MMR protein, MLH1, actually enhanced cytotoxicity at high 
GCV concentrations.  In contrast, most of the GCV/HU combination studies 
demonstrated strong synergy at concentrations of GCV below an IC90. Taken together, 
these data suggest that the combination of GCV and HU elicit synergy by decreasing 
dGTP and thus increasing GCVMP in DNA rather than through activation of MMR.   
We extended the results with MMR to screen a panel of yeast strains containing 
deletions in various DNA damage and repair genes to evaluate other pathways which 
may play a role at lower concentrations of GCV.  DNA damage repair pathways and 
checkpoints in S. cerevisiae are conserved with those in humans (37).  The yeast system 
allows for a rapid screen of many different mutants, a process which would be very 
difficult to conduct in mammalian cells due to the amount of time required to develop 
and test a large number of deletion mutants.  Results in the yeast with deletions in MMR 
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genes MLH1 or MSH2 were similar to those observed in the human cell lines lacking 
MLH1, in which differences in sensitivity to GCV only occurred at a high concentration 
of GCV.  Experiments in yeast have correctly predicted effects in human cells with other 
drugs as well.  Previous work from the Wilson laboratory and others identified the major 
Tdp1-dependent pathway for resolution of aberrant topoisomerase complexes in yeast 
(25,38,39),  findings which were subsequently confirmed in human cells (40). These data 
support the use of the yeast assay to discover other DNA damage response pathways that 
affect sensitivity to GCV.   
The yeast assay demonstrated that deletion of genes involved in HRR and cell 
cycle checkpoints caused a significant increase in sensitivity to GCV.  There are several 
mechanisms through which HRR could impact GCV cytotoxicity.  Thust et al have 
demonstrated that GCV induces sister chromatid exchanges, which usually arise from 
HRR, during the second S phase after GCV exposure (41-43).  In addition, HRR is 
required to restart a stalled replication fork (44), and we have also shown that, at 
concentrations >IC50, GCV slows replication which likely is due to  stalled replication 
forks (18).  Thus, it will be important to determine the precise role of HRR in GCV 
cytotoxicity.  
Other genes implicated in conferring sensitivity to GCV included ASF1, a histone 
chaperone involved in chromatin assembly (45).  No increase in GCV sensitivity was 
observed in strains lacking CHD1, another chromatin remodeling factor, likely indicating 
differing roles of ASF1 and CHD1 in this process.  Similarly, it has also been reported 
that deletion of CHD1 did not modify sensitivity to HU, UV radiation, or methyl 
methanesulfonate, suggesting that this protein does not play a role in DNA repair (46).     
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Deletion of SGS1, a helicase involved in HRR, and MMS4 or MUS81, which function 
together to cleave sites of stalled replication forks and lead to initiation of HRR also 
resulted in increased sensitivity to GCV.   Together these data further support a role of 
HRR in responding to GCV-induced DNA damage.  Interestingly, deletion of genes 
involved in postreplication repair and base excision repair did not confer sensitivity to 
GCV, suggesting that these pathways are not involved in protecting from GCV-mediated 
cytotoxicity. Although a study in Chinese hamster ovary cells suggested that base 
excision repair is involved in protection of cells to GCV (16),  we have not observed 
excision of GCVMP from DNA in a variety of human cell lines (4,10,27). 
Deletion of the gene for DUN1, a regulator of ribonucleotide reductase (47,48) 
which produces dNTPs for DNA replication and repair, also enhanced the sensitivity of 
yeast significantly to GCV.  The absence of this protein would result in lower dNTP 
pools, impairing DNA replication and repair following GCV-induced DNA damage.  In 
addition, lowered dNTP pools would likely result in an increase in GCVTP incorporation 
into DNA by decreasing the availability of its competitor, dGTP, another mechanism for 
increased cytotoxicity.  Although a human homolog of DUN1 has not been discovered, 
we have previously demonstrated a role for ribonucleotide reductase since its inhibition 
enhanced GCV cytotoxicity (17,18,49).   
Proteins involved in promoting cell cycle checkpoints also appear to be involved 
in recognizing GCV-mediated damage, as deletion of Ddc1, Mec3, and Rad17, yeast 
homologs of the 9-1-1 complex that responds to DNA damage in mammalian cells, and 
Rad24, the clamp loader that loads the complex onto damaged DNA, rendered the yeast 
more sensitive to GCV (50).  This complex is involved in facilitating activation of Chk1, 
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resulting in checkpoint activation and cell cycle arrest.   This arrest allows time for cells 
to repair DNA damage and can lead to activation of signaling pathways ultimately 
leading to cell death if the damage is irreparable.  These data suggest a role for this 
complex in responding to GCV-induced DNA damage, and will need to be confirmed in 
human cells. 
These results suggest a variety of mechanisms to improve therapy with HSV-
TK/GCV.  The increased sensitivity of MLH1 deficient cells to high concentrations of 
GCV (0.5-10 µM) is within a clinically relevant range, as GCV typically achieves plasma 
concentrations of 10-30 µM in patients (51-53).  Many human tumors are deficient in 
DNA damage response pathways, such as MMR (54,55).  Perhaps the most successful 
clinical trials of this therapy have been in prostate cancer (56), a tumor type in which a 
significant percentage show loss of at least one MMR protein and reduced MMR capacity 
(55).  The data presented here suggest that MMR deficient tumors would respond better 
to HSV-TK/GCV treatment than MMR proficient tumors since MMR appears to protect 
cells from GCV-mediated cytotoxicity.  Based on the data from the yeast screen, tumors 
defective in certain checkpoint pathways would also be expected to respond better to 
GCV.  Since normal tissues are generally proficient in these pathways, targeting MMR 
and checkpoint defective tumors would improve selectivity of this therapy.  Furthermore, 
these studies suggest other pathways, such as HRR, which could be targeted in 






I would like to thank Dr. Thomas Wilson for his assistance in performing the S. 
cerevisiae experiments, Anthony Iacco for generating the HSV-TK-expressing yeast 
strains utilized in this chapter, and Dr. Paul Boucher for generating the HSV-TK-
expressing HCT116 cell lines.  
 




 (1)  Greco O, Dachs GU. Gene directed enzyme/prodrug therapy of cancer: historical 
appraisal and future prospectives. J Cell Physiol 2001; 187(1):22-36. 
 (2)  Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann JL, Klatzmann D. 
Regression of established macroscopic liver metastases after in situ transduction 
of a suicide gene. Proc Natl Acad Sci U S A 1993; 90(15):7024-7028. 
 (3)  O'Malley BW, Jr., Chen SH, Schwartz MR, Woo SL. Adenovirus-mediated gene 
therapy for human head and neck squamous cell cancer in a nude mouse model. 
Cancer Res 1995; 55(5):1080-1085. 
 (4)  Boucher PD, Ruch RJ, Shewach DS. Differential ganciclovir-mediated 
cytotoxicity and bystander killing in human colon carcinoma cell lines expressing 
herpes simplex virus thymidine kinase. Hum Gene Ther 1998; 9(6):801-814. 
 (5)  Freytag SO, Paielli D, Wing M, Rogulski K, Brown S, Kolozsvary A et al. 
Efficacy and toxicity of replication-competent adenovirus-mediated double 
suicide gene therapy in combination with radiation therapy in an orthotopic 
mouse prostate cancer model. Int J Radiat Oncol Biol Phys 2002; 54(3):873-885. 
 (6)  Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are 
we going? J Natl Cancer Inst 1997; 89(1):21-39. 
 (7)  Trask TW, Trask RP, Aguilar-Cordova E, Shine HD, Wyde PR, Goodman JC et 
al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir 
administration in patients with current malignant brain tumors. Mol Ther 2000; 
1(2):195-203. 
 (8)  Smitt PS, Driesse M, Wolbers J, Kros M, Avezaat C. Treatment of relapsed 
malignant glioma with an adenoviral vector containing the herpes simplex 
thymidine kinase gene followed by ganciclovir. Mol Ther 2003; 7(6):851-858. 
 (9)  Freytag SO, Stricker H, Pegg J, Paielli D, Pradhan DG, Peabody J et al. Phase I 
study of replication-competent adenovirus-mediated double-suicide gene therapy 
in combination with conventional-dose three-dimensional conformal radiation 
therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate 
cancer. Cancer Res 2003; 63(21):7497-7506. 
 (10)  Rubsam LZ, Davidson BL, Shewach DS. Superior cytotoxicity with ganciclovir 
compared with acyclovir and 1-beta-D-arabinofuranosylthymine in herpes 
simplex virus-thymidine kinase-expressing cells: a novel paradigm for cell killing. 
Cancer Res 1998; 58(17):3873-3882. 
 (11)  Halloran PJ, Fenton RG. Irreversible G2-M arrest and cytoskeletal reorganization 
induced by cytotoxic nucleoside analogues. Cancer Res 1998; 58(17):3855-3865. 
 91 
 (12)  Wei SJ, Chao Y, Hung YM, Lin WC, Yang DM, Shih YL et al. S- and G2-phase 
cell cycle arrests and apoptosis induced by ganciclovir in murine melanoma cells 
transduced with herpes simplex virus thymidine kinase. Exp Cell Res 1998; 
241(1):66-75. 
 (13)  Tomicic MT, Thust R, Kaina B. Ganciclovir-induced apoptosis in HSV-1 
thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2 decline and 
caspase-9 activation. Oncogene 2002; 21(14):2141-2153. 
 (14)  Hamel W, Magnelli L, Chiarugi VP, Israel MA. Herpes simplex virus thymidine 
kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res 1996; 
56(12):2697-2702. 
 (15)  Beltinger C, Fulda S, Kammertoens T, Meyer E, Uckert W, Debatin KM. Herpes 
simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-
independent death receptor aggregation and activation of caspases. Proc Natl 
Acad Sci U S A 1999; 96(15):8699-8704. 
 (16)  Tomicic MT, Thust R, Sobol RW, Kaina B. DNA polymerase beta mediates 
protection of mammalian cells against ganciclovir-induced cytotoxicity and DNA 
breakage. Cancer Res 2001; 61(20):7399-7403. 
 (17)  Boucher PD, Ostruszka LJ, Shewach DS. Synergistic enhancement of herpes 
simplex virus thymidine kinase/ganciclovir-mediated cytoxicity by hydroxyurea. 
Cancer Res 2000; 60(6):1631-1636. 
 (18)  Boucher PD, Ostruszka LJ, Murphy PJ, Shewach DS. Hydroxyurea significantly 
enhances tumor growth delay in vivo with herpes simplex virus thymidine 
kinase/ganciclovir gene therapy. Gene Ther 2002; 9(15):1023-1030. 
 (19)  Gentry BG, Boucher PD, Shewach DS. Hydroxyurea induces bystander 
cytotoxicity in cocultures of herpes simplex virus thymidine kinase-expressing 
and nonexpressing HeLa cells incubated with ganciclovir. Cancer Res 2006; 
66(7):3845-3851. 
 (20)  Kunz BA. Genetic effects of deoxyribonucleotide pool imbalances. Environ 
Mutagen 1982; 4(6):695-725. 
 (21)  Bebenek K, Roberts JD, Kunkel TA. The effects of dNTP pool imbalances on 
frameshift fidelity during DNA replication. J Biol Chem 1992; 267(6):3589-3596. 
 (22)  Martomo SA, Mathews CK. Effects of biological DNA precursor pool asymmetry 
upon accuracy of DNA replication in vitro. Mutat Res 2002; 499(2):197-211. 
 (23)  Wilson TE. A genomics-based screen for yeast mutants with an altered 
recombination/end-joining repair ratio. Genetics 2002; 162(2):677-688. 
 92 
 (24)  Wilson TE, Lieber MR. Efficient processing of DNA ends during yeast 
nonhomologous end joining. Evidence for a DNA polymerase beta (Pol4)-
dependent pathway. J Biol Chem 1999; 274(33):23599-23609. 
 (25)  Vance JR, Wilson TE. Yeast Tdp1 and Rad1-Rad10 function as redundant 
pathways for repairing Top1 replicative damage. Proc Natl Acad Sci U S A 2002; 
99(21):13669-13674. 
 (26)  Carethers JM, Hawn MT, Chauhan DP, Luce MC, Marra G, Koi M et al. 
Competency in mismatch repair prohibits clonal expansion of cancer cells treated 
with N-methyl-N'-nitro-N-nitrosoguanidine. J Clin Invest 1996; 98(1):199-206. 
 (27)  Gentry BG, Im M, Boucher PD, Ruch RJ, Shewach DS. GCV phosphates are 
transferred between HeLa cells despite lack of bystander cytotoxicity. Gene Ther 
2005; 12(13):1033-1041. 
 (28)  Taverna P, Liu L, Hanson AJ, Monks A, Gerson SL. Characterization of MLH1 
and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug 
screen. Cancer Chemother Pharmacol 2000; 46(6):507-516. 
 (29)  Simon JA, Szankasi P, Nguyen DK, Ludlow C, Dunstan HM, Roberts CJ et al. 
Differential toxicities of anticancer agents among DNA repair and checkpoint 
mutants of Saccharomyces cerevisiae. Cancer Res 2000; 60(2):328-333. 
 (30)  Cejka P, Mojas N, Gillet L, Schar P, Jiricny J. Homologous recombination 
rescues mismatch-repair-dependent cytotoxicity of S(N)1-type methylating agents 
in S. cerevisiae. Curr Biol 2005; 15(15):1395-1400. 
 (31)  Osman F, Whitby MC. Exploring the roles of Mus81-Eme1/Mms4 at perturbed 
replication forks. DNA Repair (Amst) 2007; 6(7):1004-1017. 
 (32)  Natsume R, Eitoku M, Akai Y, Sano N, Horikoshi M, Senda T. Structure and 
function of the histone chaperone CIA/ASF1 complexed with histones H3 and 
H4. Nature 2007; 446(7133):338-341. 
 (33)  Cortellino S, Turner D, Masciullo V, Schepis F, Albino D, Daniel R et al. The 
base excision repair enzyme MED1 mediates DNA damage response to antitumor 
drugs and is associated with mismatch repair system integrity. Proc Natl Acad Sci 
U S A 2003; 100(25):15071-15076. 
 (34)  Zhang H, Richards B, Wilson T, Lloyd M, Cranston A, Thorburn A et al. 
Apoptosis induced by overexpression of hMSH2 or hMLH1. Cancer Res 1999; 
59(13):3021-3027. 
 (35)  Fang Y, Tsao CC, Goodman BK, Furumai R, Tirado CA, Abraham RT et al. ATR 
functions as a gene dosage-dependent tumor suppressor on a mismatch repair-
deficient background. EMBO J 2004; 23(15):3164-3174. 
 93 
 (36)  Robinson BW, Im MM, Ljungman M, Praz F, Shewach DS. Enhanced 
radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells. 
Cancer Res 2003; 63(20):6935-6941. 
 (37)  Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 
2001; 411(6835):366-374. 
 (38)  Vance JR, Wilson TE. Repair of DNA strand breaks by the overlapping functions 
of lesion-specific and non-lesion-specific DNA 3' phosphatases. Mol Cell Biol 
2001; 21(21):7191-7198. 
 (39)  Pouliot JJ, Yao KC, Robertson CA, Nash HA. Yeast gene for a Tyr-DNA 
phosphodiesterase that repairs topoisomerase I complexes. Science 1999; 
286(5439):552-555. 
 (40)  Interthal H, Chen HJ, Kehl-Fie TE, Zotzmann J, Leppard JB, Champoux JJ. 
SCAN1 mutant Tdp1 accumulates the enzyme--DNA intermediate and causes 
camptothecin hypersensitivity. EMBO J 2005; 24(12):2224-2233. 
 (41)  Thust R, Tomicic M, Klocking R, Voutilainen N, Wutzler P, Kaina B. 
Comparison of the genotoxic and apoptosis-inducing properties of ganciclovir and 
penciclovir in Chinese hamster ovary cells transfected with the thymidine kinase 
gene of herpes simplex virus-1: implications for gene therapeutic approaches. 
Cancer Gene Ther 2000; 7(1):107-117. 
 (42)  Thust R, Tomicic M, Klocking R, Wutzler P, Kaina B. Cytogenetic genotoxicity 
of anti-herpes purine nucleoside analogues in CHO cells expressing the thymidine 
kinase gene of herpes simplex virus type 1: comparison of ganciclovir, 
penciclovir and aciclovir. Mutagenesis 2000; 15(2):177-184. 
 (43)  Tomicic MT, Bey E, Wutzler P, Thust R, Kaina B. Comparative analysis of DNA 
breakage, chromosomal aberrations and apoptosis induced by the anti-herpes 
purine nucleoside analogues aciclovir, ganciclovir and penciclovir. Mutat Res 
2002; 505(1-2):1-11. 
 (44)  Helleday T. Pathways for mitotic homologous recombination in mammalian cells. 
Mutat Res 2003; 532(1-2):103-115. 
 (45)  Hayashi R, Goto Y, Tanaka R, Oonogi K, Hisasue M, Yoshida K. Transcriptional 
regulation of human chromatin assembly factor ASF1. DNA Cell Biol 2007; 
26(2):91-99. 
 (46)  Woodage T, Basrai MA, Baxevanis AD, Hieter P, Collins FS. Characterization of 
the CHD family of proteins. Proc Natl Acad Sci U S A 1997; 94(21):11472-
11477. 
 (47)  Zhou Z, Elledge SJ. DUN1 encodes a protein kinase that controls the DNA 
damage response in yeast. Cell 1993; 75(6):1119-1127. 
 94 
 (48)  Huang M, Zhou Z, Elledge SJ. The DNA replication and damage checkpoint 
pathways induce transcription by inhibition of the Crt1 repressor. Cell 1998; 
94(5):595-605. 
 (49)  Boucher PD, Shewach DS. In Vitro and in Vivo Enhancement of Ganciclovir-
Mediated Bystander Cytotoxicity with Gemcitabine. Mol Ther 2005. 
 (50)  Parrilla-Castellar ER, Arlander SJ, Karnitz L. Dial 9-1-1 for DNA damage: the 
Rad9-Hus1-Rad1 (9-1-1) clamp complex. DNA Repair (Amst) 2004; 3(8-
9):1009-1014. 
 (51)  Sommadossi JP, Bevan R. High-performance liquid chromatographic method for 
the determination of 9-(1,3-dihydroxy-2-propoxymethyl)guanine in human 
plasma. J Chromatogr 1987; 414(2):429-433. 
 (52)  Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity, 
pharmacokinetic properties and therapeutic efficacy in cytomegalovirus 
infections. Drugs 1990; 39(4):597-638. 
 (53)  Anderson RD, Griffy KG, Jung D, Dorr A, Hulse JD, Smith RB. Ganciclovir 
absolute bioavailability and steady-state pharmacokinetics after oral 
administration of two 3000-mg/d dosing regimens in human immunodeficiency 
virus- and cytomegalovirus-seropositive patients. Clin Ther 1995; 17(3):425-432. 
 (54)  Peltomaki P. Deficient DNA mismatch repair: a common etiologic factor for 
colon cancer. Hum Mol Genet 2001; 10(7):735-740. 
 (55)  Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human 
cancer. J Clin Oncol 2003; 21(6):1174-1179. 
 (56)  Freytag SO, Stricker H, Movsas B, Kim JH. Prostate cancer gene therapy clinical 











COMPARISON OF DNA MUTATIONS AND CELL CYCLE PROGRESSION 




 Ganciclovir (GCV) is an antiviral drug commonly used for cytomegaloviral 
infections in immunocompromised patients and is also in clinical trials in combination 
with herpes simplex virus thymidine kinase (HSV-TK) in a suicide gene therapy 
approach for cancer.  Previous reports have suggested that GCV is genotoxic, but the 
exact nature of the induced DNA damage is not known.  In this study, we examined the 
effects of GCV incorporation into DNA by characterizing the resulting DNA mutations 
and comparing the nature of these mutations to two other structurally related HSV-TK 
substrates, D-carbocyclic 2'-deoxyguanosine (CdG) and penciclovir (PCV).  GCV and 
CdG are similarly toxic, and PCV is 1-2 logs less cytotoxic.  GCV induced a dose-
dependent increase in mutation frequency, while concentrations of CdG and PCV >IC90 
failed to induce a significant increase in mutations.  Interestingly, GCV predominantly 
induced specific GC TA transversions which were not observed to as great an extent in 
control cells or those treated with PCV or CdG.  This specific transversion occurred in 
both mismatch repair proficient and deficient cells, and was not affected by activation of 
mismatch repair with hydroxyurea.  Analysis of cell cycle progression demonstrated that 
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GCV slowed progression through S-phase whereas CdG induced a greater G2/M block, 
but both GCV and CdG allowed cells to complete one cell cycle after drug treatment and 
divide followed by cell death in the second cell cycle.  In contrast, cells treated with PCV 
exhibited a lengthy S-phase block due to profound depression of DNA synthesis, and 
some cell death occurred in the first cell cycle after drug treatment.  These data suggest 
the inability to halt cell division after GCV or CdG treatment results in high cytotoxicity 
compared to the profound cell cycle inhibition observed with the less toxic PCV.  
Furthermore, the data demonstrate that alteration of the deoxyribose structure produced 




Ganciclovir (GCV) is a potent antiviral drug capable of eliciting multilog 
cytotoxicity at submicromolar concentrations in a variety of mammalian cell lines which 
have been engineered to express the herpes simplex virus thymidine kinase (HSV-TK) 
(1-7).  In comparison, other HSV-TK substrates such as the structurally related acyclovir 
(ACV) and the thymidine analog, 1-β-D-arabinofuranosylthymine (araT), are only 
weakly cytotoxic to human cells expressing HSV-TK (1).  However, D-carbocyclic 2'-
deoxyguanosine (CdG), also induced multi-log cell killing at low concentrations (8).   
HSV-TK facilitates phosphorylation of GCV to its 5'-monophosphate (GCVMP).  
After subsequent phosphorylation by endogenous kinases to its 5'-triphosphate (GCVTP), 
this metabolite competes with dGTP for incorporation into DNA which leads to cell 
death (9).  It was reported previously that the superior cytotoxicity of GCV compared to 
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araT and acyclovir was not due to increased accumulation of active triphosphate 
metabolite, increased incorporation into DNA, or increased apoptosis (1).  GCV induces 
a unique manner of cell death in which cells are able to complete one cell division cycle 
during and following GCV exposure; however, as they attempt to traverse S phase for a 
second time, they arrest and subsequently die.   Conversely, cells treated with araT 
arrested in the first S phase during drug exposure.   
Although these nucleoside analogs elicit their effects by incorporation into DNA, 
the resulting consequences of this incorporation, such as cell survival, differ significantly.  
Few studies have examined the events occurring downstream of GCVMP incorporation 
into DNA or characterized the specific nature of DNA damage induced by GCV.  Thust 
et al have published reports showing that GCV induced sister chromatid exchanges 
(SCEs) and structural chromosome aberrations while acyclovir and the related 
penciclovir (PCV) did not (10-14).    Interestingly, the observed SCE induction occurred 
during the second cell cycle following GCV treatment, with similar timing of the 
observed S phase arrest (1).   
This study aimed to characterize the functional consequences of incorporation of 
these nucleoside analogs into DNA to determine if this can account for the differential 
cell killing with structurally related substrates.  The ability of GCV to induce DNA 
mutations was characterized and compared to two other HSV-TK substrates, CdG and 
penciclovir (PCV).  We present findings that, despite the structural similarities of GCV, 
CdG, and PCV, they have profoundly different effects on the fidelity of DNA replication 
and mechanism of cytotoxicity. 
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Materials and Methods 
Cell Culture. HCT116 human colon carcinoma and U251 human glioblastoma cell lines 
were maintained in Dulbecco’s Modified Eagle medium and RPMI (Invitrogen Life 
Technologies, Grand Island, NY); respectively.  Media was supplemented with 2 mM L-
glutamine (Fisher Scientific, Pittsburgh, PA) for all cell lines and 10% fetal bovine serum 
(Invitrogen) for HCT116 and 10% bovine serum for U251 cells. All cells were 
maintained in exponential growth and kept in an atmosphere of 37°C and 5%CO2.  
 
Stable Gene-Expressing Cell Lines.  HCT116 0-1, HCT116 1-2, and U251 cell lines 
were transduced with a retroviral vector encoding for the Herpes Simplex Virus Type 1 
Thymidine Kinase along with the neomycin resistance gene (1).  Transgene expressing 
cells were selected and maintained with 1000 µg/mL  and 400 µg/mL G418 (Invitrogen), 
respectively.   
 
Clonogenic Cell Survival Assays.  Exponentially growing cells were treated with drug 
for 24 h, trypsinized, counted with a Coulter electronic particle counter, and diluted to 
approximately 100 viable cells per well in 6-well culture dishes.  After 10-14 days, the 
cell colonies were fixed in methanol:acetic acid (3:1), stained with 0.4% crystal violet 
(Fisher Scientific), and visually counted.  Cell survival is expressed as a fraction of the 
plating efficiency of control, non-drug treated cells.  All assays were performed at least 
twice with each data point plated in triplicate.   
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Shuttle Vector-based Mutation Assay. HCT116 and U251 cell lines were transfected 
with the pSP189 plasmid (which encodes the SV40 T antigen and mammalian origin of 
replication as well as the supF gene and an AMP resistance gene to aid in detection of the 
mutations and for growing on Amp plates, respectively (15)) using SuperFect transfection 
reagent (Qiagen).  Medium was replaced after an overnight incubation with transfection 
complexes, and drug was added for 24 h.  Following drug incubation, drug was removed 
and fresh media added.  pSP189 plasmid was harvested 24 h after the conclusion of drug 
incubation and isolated using a Qiagen Miniprep kit, incubated with DpnI (Invitrogen) to 
remove unreplicated plasmid DNA, and further purified by a phenol/chloroform 
extraction followed by precipitation with isopropanol/ethanol and dissolved in 0.5x TE 
(pH 7.5).   
Transformation was accomplished via electroporation with 1 µL of TE containing 
plasmid DNA and 20 µL of electrocompetent MBM7070 E. coli. The transformation 
mixtures were plated onto agar plates containing 100 µg/mL ampicillin (Roche), 50 
mg/mL isopropyl-L-thio-B-D-galactopyranoside (Invitrogen), and 20 mg/mL 5-bromo-4-
chloro-3-indolyl-ß-D-galactopyranoside (Roche).  Colonies were counted, and mutation 
frequencies were calculated as number of white colonies / number of (white + blue) 
colonies. DNA from mutant clones was isolated and sequenced at the University of 
Michigan DNA Sequencing Core using the 20-mer primer (5'-
GGCGACACGGAAATGTTGAA). 
 
Cell cycle progression and DNA synthesis.  Flow cytometric analysis was performed as 
previously described (16).  Briefly, at the conclusion of the drug incubation, cells were 
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pulse labeled with 30 µM BrdUrd for 15 min, and then harvested by trypsinization, 
counted, and fixed in cold 70% ethanol. Fixed cells were resuspended in 0.5 mg/ml 
RNAse A (Boehringer Mannheim, Indianapolis, IN, USA) and incubated for 30 min at 
37°C. Cells were then subjected to 0.1 N HCl containing 0.7% Triton X-100 (10 min on 
ice), followed by a 95°C incubation for 15 min in sterile water. One hundred µl of PBS 
containing 0.5% Tween 20 and 5% calf serum (PBT) was added to each cell pellet 
followed by the addition of 100 µl of anti-BrdUrd mouse IgG1 antibody (1:100 dilution; 
PharMingen, San Diego, CA, USA) and incubation for 30 min at room temperature. After 
centrifugation, 150 µl of FITC conjugated goat anti-mouse IgG antibody (1:20-35 
dilution; Sigma Chemical, St Louis, MO, USA) was added to the pellet, mixed gently, 
and incubated for 30 min at room temperature. Samples were centrifuged and 
resuspended in 0.5 ml of 18 µg/ml propidium iodide containing 40 µg/ml RNAse A.  
Treated cells were placed in the dark for a 1 hr before cell cycle analysis using a Coulter 
EPICS Elite ESP flow cytometer (Coulter, Hialeah, FL, USA). Cell cycle data were 
further analyzed using WinMDI software (ver 2.8.8) provided by Joseph Trotter of The 
Scripps Research Institute (La Jolla, CA, USA). Percent DNA synthesis was determined 
by the change in the mean fluorescence intensity of BrdUrd incorporating cells.  
 
Results 
In order to determine the ability of GCV to induce mutations, a well characterized 
plasmid-based shuttle vector assay was employed (15). The pSP189 plasmid encodes the 
cDNA for supF which corrects an amber mutation in the β-galactosidase gene in E coli, 
and a mutation at nearly any site in the supF sequence prevents expression of β-
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galactosidase.  Replication of the plasmid in human tumor cells during drug incubation 
followed by transfer of the plasmid DNA to E. coli allows blue/white screening of supF 
mutations in bacterial colonies stained with X-gal.  U251TK cells were transfected with 
the pSP189 plasmid, incubated with GCV for 24 hr, plasmid DNA was harvested 24 hr 
afer drug washout (to allow completion of DNA replication) followed by electroporation 
into E. coli.  Using a broad range of GCV concentrations (IC10-IC90), a dose dependent 
increase in plasmid mutation frequency was observed (Figure 4.1).  At concentrations of 
GCV ≥ 0.1 µM (IC75), the increase in mutation frequency was significantly different from 
control, achieving a nearly 4-fold increase at a concentration of 1 µM.  Analysis of the 
nature of the resulting mutations revealed that GCV induced a predominance of GC TA 
transversions (Figure 4.2).  Interestingly, at 0.03 and 0.05 µM GCV there was no 
significant increase in mutation frequency, yet 72% and 56% of the total mutations were 
GC TA compared to 33% in control cells.  At the higher concentrations of GCV, up to 
81% of the mutations were GC TA.  The total increase in mutation frequency can be 
accounted for by the increase in GC TA mutations, as there was no increase in any of 
the other mutations.   
Further analysis of the mutations revealed two hot spots in the supF tRNA 
sequence where the majority of GCV-induced mutations GC TA occurred (Figure 4.3).  
Following GCV exposure, the most frequent mutation was C A at position 20 (C20A), 
accounting for 15-53% of total mutations.  In addition, the prevalence of this mutation 
increased at higher GCV concentrations.  The second most common mutation following 
treatment with GCV was C A at position 48 (C48A).  Although mutations at these sites 
were observed in control cells, they accounted for less than 5% of the total number of 
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Figure 4.1. GCV induces a dose dependent increase in mutation frequency.  pSP189 
plasmid mutation frequency in U251tk cell line following exposure to increasing 
concentrations of GCV. Cells were transfected with the pSP189 plasmid overnight and 
incubated with 0.03 -1 µM GCV for 24 h.  Plasmids were harvested 24 h after drug 
removal, and DNA from replicated plasmids was electroporated into MB7070 E. coli and 
mutations were determined. Mutation frequency was calculated as the number of white 
colonies / total number of colonies counted.  Columns, average of at least three separate 
experiments; bars, SE; asterisks, significantly greater than the corresponding non-drug 
treated control.  











Figure 4.2. GCV induces a predominance of GC TA transversions.  pSP189 
plasmid mutation frequency in U251tk cell line following exposure to increasing 
concentrations of GCV. Cells were transfected with the pSP189 plasmid overnight and 
incubated with 0.03 -1 µM GCV for 24 h.  Plasmids were extracted 24 h after drug 
removal and mutations were determined.  Plasmids were extracted from mutant colonies 
and submitted for DNA sequencing.  n=total number of mutants sequenced/total number 
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Figure 4.3. Distribution of single base substitutions in the supF cDNA replicated in 
U251tk cells.   U251tk cells were transfected with pSP189 plasmid overnight and 
incubated with 0-1µM GCV for 24 h. Plasmids were extracted 24 h after drug removal 
and electroporated into E. coli.   Plasmids were extracted from mutant colonies and 
submitted for DNA sequencing.  The supF coding sequence is shown with the mutations 
at the individual sites.  The asterisks denote frequently mutated positions with the 
percentage stating percentage of total base substitutions occurring at this point.  n=total 
number of white colonies. 
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mutations.  The pSP189 plasmid contains an 8-bp signature sequence, which provides 
over 65,000 possible signature sequences within the plasmid population.  In order to 
determine that mutations occurring at the same location in supF tRNA were unique, the 
sequence of the 8 bp signature was analyzed and it was determined that each plasmid 
carrying the mutations had different signature sequences, and thus the predominance of 
the GC TA mutations was not due to overrepresentation of a single plasmid.    
Previously we have determined that the absence of a functional MMR pathway 
enhances cytotoxicity at high concentrations (>IC90) of GCV.  We wished to determine 
whether this difference in cytotoxicity was related to the nature or frequency of mutations 
induced.  U251 cells are MMR-proficient, so we investigated the role of MMR status on 
mutations induced by GCV using HCT116TK colon carcinoma cells that are deficient (0-
1TK) or proficient (1-2TK) in MMR.  In addition, hydroxyurea (HU) was used to 
produce an imbalance in dNTP pools resulting in activation of MMR, allowing us to 
study the role of MMR activation on the nature and frequency of mutations.  Cell survival 
studies demonstrated similar GCV sensitivity in the MMR-deficient 0-1TK cells 
compared to the MMR-proficient 1-2TK cells based on IC50 values (0.57 ± 0.04 and 0.39 
± 0.09, respectively; p=0.11) (Table 4.1).  The addition of HU at 1 or 3 mM decreased the 
IC50 for GCV in the MMR-deficient 0-1TK (0.41 ± 0.06 and 0.34 + 0.01 µM, 
respectively).  In contrast, HU increased the IC50 for GCV by >2-fold in the MMR-
proficient 1-2TK cells (0.77 ± 0.19 and >1.0 µM at 1 and 3 mM HU, respectively).     
In order to determine if the enhanced cytotoxicity with GCV + HU in the 
HCT116 0-1TK (MMR-deficient) cells compared to the antagonism of cytotoxicity in the 















   
MMR-deficient 0 0.57 ± 0.04  
HCT116 0-1TK 1 0.41 ± 0.06 
 3 0.34 ± 0.01 
   
   
MMR-proficient 0 0.39 ± 0.09 
HCT116 1-2TK 1 0.77 ± 0.19  
 3 >1.0* 
   
 
 
Table 4.1. The addition hydroxyurea decreases the IC50 for GCV in MMR-deficient 
HCT116 0-1TK cells but increases the IC50 for GCV in the MMR-proficient 
HCT116 1-2TK cells. Exponentially growing U251tk cells were treated with GCV 
and/or HU for 24 hours.   Clonogenic cell survival was determined and expressed as a 
fraction of plating efficiency for untreated cells.  Values represent Mean ± SE       
                           




nucleotides in DNA, the mutation frequency was measured following treatment with 
GCV ± HU in both cell lines.  The mutation frequency of untreated cells was 
significantly greater in the MMR-deficient 0-1TK cell line than in the MMR-proficient 1-
2TK cell line (0.11 ± 0.01% and 0.06 ± 0.01%, respectively, p=0.03) (Figure 4.4).  A 24 
hr incubation with 1 µM GCV resulted in similar mutation frequencies in both the MMR-
deficient 0-1TK and MMR-proficient 1-2TK cell lines (0.17 ± 0.02% and 0.14 ± 0.02%, 
respectively) that were significantly different from their corresponding controls (p<0.05). 
Treatment with 2 mM HU resulted in a significant increase in mutation frequency in the 
MMR-deficient 0-1TK cells (0.28 ± 0.03%; p=0.005), but not in the MMR-proficient 1-
2TK cells (0.03 ± 0.01%; p=0.24) compared to untreated controls, as expected.  The 
combined treatment with GCV and HU produced a further increase in mutation frequency 
in the MMR-deficient 0-1TK cell line (0.39 ± 0.06%).  However, in the MMR-proficient 
1-2TK cell line, the combination of GCV and HU resulted in a significant decrease in the 
mutation frequency (0.06 ± 0.01 %, p=0.01) compared to cells treated with GCV alone. 
Further analysis of the nature of the resulting mutations again revealed that GCV 
induced a predominance of GC TA transversions in both the MMR-deficient 0-1TK and 
MMR-proficient 1-2TK cell lines (49% and 88%, respectively) whereas this specific 
mutation accounted for only 29% and 12% of the total mutations in control cells from 
both cell lines.  Furthermore, HU induced single base substitutions in which no single 
type of mutation accounted for more than 35% of the total mutations (Figures 4.5A and 
B).  Interestingly, the combined treatment with GCV and HU in the MMR-deficient 0-
1TK cell line resulted in a pattern of mutations more closely resembling those induced by 









































































Figure 4.4.   pSP189 plasmid mutation frequency in MMR-deficient and proficient 
HCT116tk cell lines following exposure to GCV and/or HU. Cells were transfected 
with the pSP189 plasmid overnight and incubated with 1µM GCV and/or 2 mM HU for 
24 h.  Plasmids were extracted 24 h after drug removal and mutations were determined.  
Mutation frequency was calculated as the number of white colonies / total number of 
colonies counted.  Columns, average of at least three separate experiments; bars, SE; 


















Figure 4.5.   Nature of mutations in supF sequence of pSP189 plasmids replicated in 
MMR-deficient and proficient HCT116tk cell lines following exposure to GCV 
and/or HU. Nature of mutations in the supF sequence in pSP189 plasmids replicated in 
(A) MMR-deficient HCT116 0-1tk and (B) MMR-proficient HCT116 1-2tk. Cells were 
transfected with the pSP189 plasmid overnight and incubated with 1 µM GCV and/or 2 
mM HU for 24 h.  Plasmids were extracted 24 h after drug removal and mutations were 
determined. Plasmids were extracted from mutant colonies and submitted for DNA 
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that the combination resulted in a decrease in the overall mutation frequency, GC TA 
mutations still predominated.  The C20A mutation predominated in the MMR-proficient  
1-2TK cells (55%) (Figure 4.6) and but represented only 7% of total mutations in the 
MMR-deficient cells (Figure 4.7).  The addition of HU resulted in a reduction of the 
C20A mutations in both cell lines; however they still represented 31% of total mutations 
in the MMR-proficient 1-2TK cell line, while they were absent in the MMR-deficient 0-
1TK cell line. 
In order to determine if the pattern of mutations induced by GCV were specific to 
deoxyguanosine analogs, mutations induced by two other structurally related compounds, 
CdG and PCV, were analyzed.  The structures of these three drugs are similar as they all 
have changes to the deoxyribose moiety of deoxyguanosine with no alterations of the 
base (Figure 4.8A).    GCV and CdG are similarly toxic in U251tk cells, as reported 
previously (8), whereas PCV was 1-2 logs less cytotoxic at equimolar concentrations 
(Figure 4.8B).  Neither 1 µM CdG (IC99) nor 10 µM PCV (IC93) produced a significant 
increase in mutation frequencies compared to control (Figure 4.9A).  In addition, there 
was not a predominance of any specific mutation following exposure to these drugs 
(Figure 4.9B) and neither the C20A or C48A mutation occurred with either of these two 
drugs (data not shown). 
Because the changes in structure of these nucleoside analogs resulted in a distinct 
difference on induction of mutations, we wished to determine if these drugs differed with 
respect to the mechanism by which they cause cytotoxicity.  Previously we have 
demonstrated a unique pattern of cell cycle progression after treatment with GCV, 


























Figure 4.6.  Distribution of single base substitutions in the supF cDNA replicated in 
MMR-deficient HCT116 0-1tk cells.  MMR-deficient HCT116 0-1tk cells were 
transfected with pSP189 plasmid overnight and incubated 1 µM GCV and/or 2 mM HU 
for 24 h.  Plasmids were harvested 24 h after drug removal and electroporated into E. 
coli.   Plasmid DNA was extracted from mutant colonies and submitted for DNA 
sequencing.  The supF coding sequence is shown with the mutations at the individual 
sites.  The asterisks denote frequently mutated positions with the percentage indicating 
the percentage of total base substitutions occurring at this position.  n=total number of 


























Figure 4.7. Distribution of single base substitutions in the supF cDNA replicated in 
MMR-proficient HCT116 1-2tk cells.  MMR-proficient HCT116 1-2tk cells were 
transfected with pSP189 plasmid overnight and incubated with 1 µM GCV and/or 2 mM 
HU for 24 h.  Plasmids were harvested 24 h after drug removal and electroporated into E. 
coli.   Plasmids were extracted from mutant colonies and submitted for DNA sequencing.  
The supF coding sequence is shown with the mutations at the individual sites.  The 
asterisks denote frequently mutated positions with the percentage indicating the 






















Figure 4.8 Sensitivity of U251tk cells to GCV, CdG, and PCV (A) Structures of GCV, 
CdG, and PCV.  (B) Sensitivity of U251tk cells to GCV, CdG, and PCV.  Exponentially 
growing U251tk cells were exposed to increasing concentrations of indicated drug for 24 
hours.  Clonogenic cell survival was determined and expressed as a fraction of plating 








































Figure 4.9. pSP189 plasmid mutation frequency in U251tk cell line following 
exposure to CdG and PCV. (A) pSP189 plasmid mutation frequency in U251tk cells 
following exposure to CdG or PCV. Cells were transfected with the pSP189 plasmid 
overnight and incubated with 1 µM CdG or 10 µM PCV for 24 h.  Plasmids were 
harvested 24 h after drug removal and mutations were determined.  Mutation frequency 
was calculated as the number of white colonies / total number of colonies counted.  
Columns, average of at least three separate experiments; bars, SE; asterisks, significantly 
greater than the corresponding non-drug treated control.   (B) Nature of mutations in the 
supF sequence in pSP189 plasmids replicated in U251tk cells.  Plasmid DNA was 
extracted from mutant colonies and submitted for DNA sequencing.  n=total number of 
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similar or different effects.  Thus we evaluated the effect of these drugs on cell cycle 
progression by a dual parameter flow cytometry technique able to separate cells based  
both on DNA content (propidium iodide staining) and rate of DNA synthesis (amount of 
BrdUrd incorporated into DNA).  Consistent with a previous report examining DNA 
content alone (1), cells treated with GCV were slowed in S phase during a 24 hour 
incubation with GCV and for 12 hours after drug removal (Figures 4.10 and 4.11 and 
Table 4.2).  At 24 hours after drug removal, cells began to progress through the cell 
cycle, although there was still a high proportion in G1 and early S phase.  These data and 
the 2-fold increase in cell number demonstrated that these cells were completing the cell 
cycle and undergoing division.  At 0 and 12 h after GCV washout, DNA synthesis, as 
measured by mean BrdUrd fluorescence, was similar to control cells.  GCV-treated cells 
continued to accumulate in S phase through 72 hours following drug removal. 
Similar to GCV-treated cells, following exposure to CdG cells were able to 
continue through the cell cycle one time following drug exposure, as indicated by an 
approximately 2-fold increase in cell number at 36 hr after drug washout (Table 4.2).  
However, they accumulated in G2/M during drug incubation and beginning again at 24 
hours after drug washout. In addition, DNA synthesis was lower compared to cells 
treated with GCV.    
PCV-treated cells exhibited a pattern of cell cycle progression distinct from either 
GCV or CdG.  Within 12 hr after drug addition, the cells accumulated in early S phase 
and remained there until at least 12 hr after drug washout, likely due to the strong 
inhibition of DNA synthesis.  After drug washout, cells progressed from early to mid and 
late S phase through 48 hours after drug washout.  There was a continuous decrease in 
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Figure 4.10.  Effects of GCV, CdG, and PCV on the cell cycle distribution of U251tk 
cells during drug incubation.  Cells were incubated with 1 µM GCV, 1 µM CdG, or 50 
µM PCV for 24 h. Cells were analyzed at indicated time points during drug incubation 
Cells were incubated with 30 µM BrdUrd for 15 min before harvest. Cells were then 
prepared for dual parameter flow cytometry to determine BrdUrd and DNA content as 
described in Materials and methods. Control represents a 24 h period without drug 
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Figure 4.11.  Effects of GCV, CdG, and PCV on the cell cycle distribution of U251tk 
cells following drug removal.  Cells were incubated with 1 µM GCV, 1 µM CdG, or 50 
µM PCV for 24 h.   Drug containing medium was removed following the 24 h incubation 
and replaced with fresh drug-free medium. Cells were analyzed at indicated time points 
after drug removal. Cells were incubated with 30 µM BrdUrd for 15 min before harvest. 
Cells were then prepared for dual parameter flow cytometry to determine BrdUrd and 
DNA content as described in Materials and methods. Control represents a 24 h period 


















    (%) (%) (%) (%) (%) (%) (x 106) (% Control) 
              
Control 0 h 73.2 5.9 5.3 5.2 16.4 10.4 1.94 100 
              
GCV -12 h 10.7 55.8 19.0 11.2 86.1 3.2 0.96 39 
  0 h 17.8 16.9 43.8 16.5 77.2 4.9 1.06 104 
  12 h 10.0 23.9 28.8 28.1 80.8 9.2 1.19 103 
  24 h 31.7 34.8 12.2 9.4 56.4 12.0 1.81 68 
  36 h 31.6 40.7 14.0 7.0 61.7 6.7 1.6 35 
  48 h 36.0 28.9 18.3 6.2 53.4 10.6 2.06 18 
  72 h 22.2 47.1 15.7 12.1 74.9 2.9 0.74 12 
              
CdG -12 h 22.2 26.6 14.1 10.7 51.4 26.4 1.18 45 
  0 h 33.6 27.8 13.0 10.8 51.5 14.8 1.49 62 
  12 h 17.3 45.5 16.8 7.1 69.4 13.3 1.83 46 
  24 h 23.3 17.6 21.1 15.5 54.2 22.4 1.84 52 
  36 h 27.7 22.0 17.4 10.0 49.5 22.8 2.02 38 
  48 h 31.1 16.5 15.3 9.9 41.7 27.2 1.78 36 
  72 h 18.0 12.1 12.7 15.5 40.3 41.8 1.42 26 
              
PCV -12 h 27.3 39.9 17.9 10.2 68.0 4.7 0.93 11 
  0 h 8.7 66.8 16.6 6.5 89.9 1.3 0.83 26 
  12 h 2.6 77.2 15.7 3.8 96.7 0.7 0.86 37 
  24 h 6.0 46.2 35.8 10.5 92.5 1.5 0.81 25 
  36 h 2.7 56.8 31.4 8.7 97.0 0.3 0.62 30 
  48 h 6.4 24.3 36.2 27.8 88.3 5.3 0.54 31 
  72 h 40.6 12.7 12.5 11.7 36.9 22.5 0.29 16 
 
Table 4.2. Effect of GCV, PCV, and CdG on the cell cycle distribution of U251tk 
cells. Effects of GCV, CdG, and PCV on the cell cycle distribution of U251tk cells.  Cells 
were incubated with 1 µM GCV, 1 µM CdG, or 50 µM PCV 24 h.   Drug containing 
medium was removed following the 24 h incubation (time=0 h) and replaced with fresh 
drug-free medium. Cells were analyzed at indicated time points during drug incubation (-
12 h) and after drug removal. Cells were incubated with 30 µM BrdUrd for 15 min before 
harvest. Cells were then prepared for dual parameter flow cytometry to determine BrdUrd 
and DNA content as described in Materials and methods. Control represents a 24 h period 
without drug addition. Results of a single reproducible experiment are shown. 
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cell number during and after PCV-exposure, suggesting that the proportion of G1 and 
G2/M cells observed at 72 hours after drug washout was higher because many of the S 
phase cells had died.  
 
Discussion 
 Results presented here demonstrate that GCV induces a dose-dependent increase 
in mutation frequency with a predominance of GC TA mutations.  The unique pattern 
of mutations observed following exposure to GCV did not occur following treatment with 
two structurally similar HSV-TK substrates, CdG or PCV.  Despite the fact that these 
nucleoside analogs all elicit cytotoxicity through incorporation into DNA, the 
consequences of this incorporation differ greatly, as demonstrated by distinct effects on 
DNA replication fidelity and cell cycle progression, resulting in significant differences in 
cytotoxicity. 
We wished to determine whether the high cytotoxicity and delayed induction of 
DNA damage observed with GCV is due to the induction of excessive or unique 
mutations in DNA.  Although GCV did induce a dose-dependent increase in mutation 
frequency, this alone is likely not responsible for the majority of GCV-induced 
cytotoxicity since there was not a significant increase in mutations at concentrations of 
GCV <IC50 where significant cell death was observed.  The induction of GC TA 
mutations did occur at these lower drug concentrations.  Although it may be possible that 
these specific mutations have especially deleterious effects, there are few scenarios in 
which mutations are sole contributors to cytotoxicity.   
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In previous studies characterizing structural effects of GCV incorporation into 
DNA, oligonucleotide duplexes were synthesized with and without GCVMP.  Addition 
of GCVMP resulted in a decrease in melting temperature of 6.5°C decrease per drug 
residue (17), and disruption of the deoxyribose ring resulted in decreased stability of 
DNA.  Determination of the solution structure of these GCVMP-containing duplexes 
demonstrated that the most significant distortions occurred at the site of GCVMP 
incorporation with a distinct kink in the sugar-phosphate backbone that extended two 
bases after GCVMP (Figure 4.12 and (18)).  The authors hypothesized that this distortion 
would result in the pausing of DNA polymerases.  It is intriguing to speculate that, with 
this pausing due to the presence of GCVMP, the DNA polymerases may insert incorrect 
nucleotides which would account for the induction of mutations observed in the studies 
presented here.   
There are two possible explanations for the appearance of the more frequent 
C20A and C48A mutations.  It is possible that insertion of GCVMP in a specific 
sequence prior to a required C residue alters the regional DNA conformation such that 
addition of an A is favored.  This could be due to the acyclic nature of GCV which may 
allow more flexibility of the DNA structure, as suggested by Marshalko et al (17).   Due 
to the small coding sequence of the supF cDNA, it was not possible to evaluate sequence-
specific effects in this study, but would be of interest in future studies.  In translesional 
synthesis in Escherichia coli, dAMP is preferentially incorporated opposite abasic sites in 
a phenomenon known as the “A rule” (19,20).  If the A rule also applies to mammalian 




Figure 4.12. Effect of GCVMP incorporation on DNA structure. Structure of (A) 
control and (B) GCV-containing DNA duplexes. Control: 5'-CTGGATCCAG-3'  GCV: 







of the active site of the polymerase and an A being inserted by default, thus resulting in 
the predominance of C A mutations. 
The assay utilized in this study involves the replication of plasmid in both human 
cell lines and bacteria, and thus we cannot be certain that these mutations occurred during 
replication in the human cells or as a consequence of GCVMP incorporation in the 
nascent strand with subsequent mutation occurring in the bacteria.  However, the 
likelihood that the mutations occurred during replication of the plasmids in human cells is 
supported by reports that GCV is genotoxic and carcinogenic in animal models which 
suggest a similar ability to induce mutations in replicating genomic DNA of mammalian 
cells. 
The unique GCV-associated mutations were neither detected nor repaired by 
MMR, since the mutations predominated both in MMR-proficient U251TK and HCT116 
1-2TK cell lines.  A higher percentage of GC TA mutations occurred in the MMR-
proficient cell lines than in the MMR-deficient 0-1TK cell line, further demonstrating 
that these specific misincorporations are not repaired by MMR.  The higher frequency of 
GC TA mutations in the MMR-proficient cell lines did not translate into increased cell 
death, further demonstrating that these mutations cannot be solely responsible for the 
cytotoxicity of GCV.  In addition, the data suggest that the enhancement of GCV 
cytotoxicity with HU in the MMR-deficient cells may be due to an increase in errors in 
DNA replication which are induced by HU.  However, in the MMR-proficient HCT116 
1-2TK cell line, the addition of HU activates MMR which decreases replication errors, 
resulting in antagonistic cytotoxicity. 
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We have shown in several different cell lines that GCVMP is well retained in 
DNA (1,4,6), suggesting that MMR is not capable of excising all of the fraudulent 
nucleotide.  However, activation of MMR may result in the repair of other 
misincorporations.  Although the mutation frequency with GCV is similar between MMR 
proficient and deficient cell lines, there is a greater predominance of GC TA mutations 
in MMR proficient HCT116 and U251 cell lines, suggesting that these result from 
specific misincorporations which are not repaired by MMR.  Alternatively, it is possible 
that attempted repair of GCVMP incorporation by MMR results in the production of 
GC TA mutations by polymerase δ during the resynthesis step of the repair process.  In 
addition to depletion of MMR, inhibition of DNA polymerase β, a gap-filling DNA 
repair polymerase, also sensitizes cells to GCV (21).  These data demonstrate that there is 
a cellular repair response initiated by the presence of GCVMP in DNA.  The presence of 
GCVMP in the template strand may cause polymerase δ or ε to pause at the site of 
incorporation, resulting in a stalled replication fork and the observed cell cycle arrest in S 
phase (Figure 4.13).  A similar scenario could occur if the lesion was on the lagging 
strand, with inhibition of the polymerase α/DNA primase complex.  Further research 
characterizing the interaction of GCVTP and GCVMP-containing DNA with DNA repair 
polymerases will increase our knowledge of the mechanism by which GCV induces cell 
death. 
.  Unlike GCV, neither CdG nor PCV induced a significant increase in mutation 
frequency, even at similarly toxic concentrations.  CdG and PCV also did not alter the 
proportion of induced mutations.  We have not observed this predominance of specific 






























Figure 4.13. Proposed mechanism of cell cycle arrest in response to GCV.  When 
DNA replication machinery encounters GCVMP ( ) in the template strand during DNA 
synthesis, the DNA polymerase complex stalls.  This stalled replication fork may be 
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deoxycytidine, 1-β-D-arabinofuranosylcytosine, 5-fluoro-2'-deoxyuridine, and araT ((22); 
data not shown).  Although very similar in structure to GCV, CdG and PCV did not 
induce this particular mutation nor did they produce an increase in other mutations under 
the conditions tested here.  
 Previous reports have demonstrated that GCV is more genotoxic than other HSV-
TK substrates.  ACV induced SCEs and chromosomal aberrations immediately after drug 
exposure, but only at very high concentrations, whereas GCV induced more SCEs and 
chromosomal aberrations at concentrations below IC50 and these events occurred during 
the second cell cycle after drug exposure (11,23).  SCEs occur as a result of homologous 
recombination (24).  This pathway may be activated in response to GCV-induced DNA 
damage, resulting in the formation of SCEs.  PCV exposure resulted in significantly less 
plasmid mutations than GCV at both equimolar and equitoxic concentrations (12).  
Although there is no direct evidence that GCV is carcinogenic in humans, data presented 
here and in other reports describing the genotoxic properties of GCV indicate that the 
possible genetic risk of GCV should be considered.  Studies of the long-term effects of 
GCV-induced genotoxic events in humans are warranted.  
In addition to the differences in replication fidelity, the three deoxyguanosine 
analogs differed with respect to cell cycle progression.  As we have reported previously, 
cells treated with GCV are able to complete one round of cell division following drug 
exposure and arrest in the subsequent S phase.  This suggests that the observed S phase 
arrest is due to the presence of GCVMP in the template during DNA synthesis.  Although 
GCV caused an S phase arrest and CdG produced more of a block in G2/M, following 
exposure to either of these drugs cells were able to progress through the cell cycle.  On 
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the other hand, the less cytotoxic PCV caused a more profound decrease in the rate of 
DNA synthesis compared to GCV and CdG with a strong delay in cell cycle progression.  
Similarly, araT, was previously reported to arrest cells in the first S phase during drug 
incubation but resulted in low cytotoxicity.  This suggests that it is the ability of cells to 
divide with GCV or CdG present in their DNA which accounts for their greater cytotoxic 
effects.   
While many nucleoside analogs elicit their effects by incorporating into DNA, the 
mechanism by which cells die and the extent of cytotoxicity is not always the same.  The 
structurally related nucleoside analogs investigated here caused profoundly different 
interactions with DNA and distinct effects on cell cycle progression, resulting in 
differential cell killing.  Further characterization of the consequences of DNA 
incorporation for nucleoside analogs will help in the development of more efficacious 
antitumor drugs.   
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The major goal of this dissertation was to elucidate the mechanism by which 
GCV induces cell death in order to determine why GCV is more cytotoxic than other 
related drugs.  Although HSV-TK/GCV gene therapy for cancer has been studied for 
nearly two decades, the mechanism of its cytotoxicity is still not completely understood.  
In recent years, the majority of published reports on this therapeutic approach involve 
methods of enhancing GCV cytotoxicity, mostly by the addition of other drugs or 
improvement of vector delivery of the HSV-TK gene, but mechanistic studies have been 
largely absent.   
GCV is important because it is significantly more cytotoxic than other drugs: it 
has the ability to induce more cell death than most other nucleoside analogues under 
similar conditions (1).  This powerful antitumor activity combined with a selective mode 
of delivery has great potential to improve the efficacy of cancer treatment while sparing 
normal tissue toxicity.  The overall goal of this study was to elucidate the mechanism(s) 
for the superior cytotoxicity of GCV by characterizing the amount of DNA damage 
caused by GCV, its rate of repair, and the role of specific repair pathways.  In addition, 
specific mutations in DNA induced by GCV were identified and compared to those 
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induced by other, less cytotoxic drugs.  Understanding the lesions produced and the 
pathways that attempt to repair the GCV-induced lesions will allow us to improve this 
gene therapy approach to cancer treatment, as well as develop new drugs and targets to 
induce multi-log cell killing.   
 The studies presented here characterized DNA damage induced by GCV and 
repair pathways involved in responding to this damage.  In Chapter II, we measured γ-
H2AX foci as an indicator of GCV induced DNA damage.  During GCV exposure, high 
levels of γ-H2AX foci are induced, however the subsequent decrease in this damage after 
drug removal suggests that this is repairable.  Although there is not a complete cell cycle 
arrest during GCV incubation, cells are slowed in S phase (1).  It has been reported that γ-
H2AX foci are formed at stalled replication forks and do not solely represent DNA 
double strand breaks (2-4).  This first increase in DNA damage may indicate slowing or 
stalling of replication machinery caused either by inhibition of DNA polymerases or 
reluctant extension of DNA following GCVMP incorporation, which is overcome after 
drug removal.   
Coincident with the initial increase in γ-H2AX foci, only a small increase in 
Rad51 foci was also detected, suggesting that homologous recombination repair (HRR) is 
involved possibly to a minor degree in the repair of the initial damage.  The second 
increase in DNA damage, measured by γ-H2AX foci, occurs after cells have divided and 
correlates with the timing of cell cycle arrest.  This suggests that cells are not able to 
repair this damage, and this second onset of damage is what leads to cell death.  It is 
possible that, when DNA replication machinery encounters GCVMP in template DNA, it 
causes replication to cease and replication forks to collapse.  The large increase in Rad51 
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foci formed after drug washout and immediately preceding the second increase in γ-
H2AX-detected DNA damage suggests that failed HRR may account for the lesions 
responsible for GCV cytotoxicity.  The increased sensitivity of HRR-deficient yeast to 
GCV demonstrates that HRR is required to survive GCV-induced damage.  Previous 
reports demonstrated that GCV induces sister chromatid exchanges, which also suggests 
a role for HRR in responding to GCV-induced DNA damage (5,6).  HRR may be able to 
repair lesions or stalled replication forks during the first round of cell division during and 
following GCV exposure, thus sparing cells from death at this point.  However, during 
the second cell cycle there is a strong induction of HRR which is unable to repair the 
second increase in DNA damage, resulting in cell cycle arrest and death.  It will be 
interesting to directly measure the effect of inhibiting HRR on the induction of DNA 
damage with GCV to determine whether it is truly involved.  
In contrast, araT, which is incorporated into DNA at >20 fold higher levels than 
GCV at similarly toxic concentrations (1), induces 7-fold less DNA damage than GCV as 
measured by γ-H2AX foci.  These data demonstrate that cells are much more sensitive to 
GCVMP in DNA than araTMP, and the result of incorporation of these nucleoside 
analogs is quite different.  Because it has a complete sugar ring, the presence of araTMP 
in DNA may have less of an effect on DNA stability than GCVMP which is acyclic.  
While both drugs are well retained in DNA after drug washout, surviving cells harboring 
araTMP resume DNA synthesis and cell cycle progression whereas GCVMP causes a 
permanent block in the second S-phase.  This suggests that araTMP may serve as an 
adequate substrate in template DNA, but GCVMP does not.  This could result in the 
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polymerase stalling or dissociating from the replication fork, activating cell signaling 
pathways leading to cell cycle arrest and ultimately death.    
 Because we wanted to focus on the consequences of GCV incorporation into 
DNA, it was logical to investigate repair pathways involved in responding to this 
damage.  It had previously been reported that inhibition of DNA polymerase β sensitized 
cells to GCV (7). This polymerase has been implicated in DNA repair (8), suggesting that 
GCVMP incorporation is subject to repair.  In order to more quickly and easily assay a 
wide variety of DNA repair pathways than would be possible in mammalian cells, in 
Chapter III we utilized a yeast-based screen of 96 DNA damage response mutants for 
increased sensitivity to GCV.  Yeast deficient in genes involved in HRR, cell cycle 
checkpoints and, to a lesser extent, mismatch repair (MMR) exhibited significantly 
increased sensitivity to GCV, suggesting a role for these pathways in protecting from 
GCV-mediated cytotoxicity.  We had already demonstrated a role for HRR in response to 
GCV in mammalian cells by showing that Rad51 foci were induced following exposure 
to GCV, and the results in yeast also implicated HRR in repairing GCV-induced lesions.  
Due to the inherent resistance of the yeast to GCV, we were unable to identify genes 
which conferred resistance to GCV when deleted. While the yeast assay allowed us to 
examine many DNA repair mutants for increased sensitivity to GCV and results in 
human cells have confirmed a role for MMR and HRR, the yeast results implicating cell 
cycle checkpoints in GCV cytotoxicity must be verified in mammalian cells. 
In order to further characterize the role of MMR in responding to GCV-induced 
DNA damage, we characterized the sensitivity of HSV-TK-expressing HCT116 cell lines 
which are matched for MMR proficiency and deficiency and determined that the MMR-
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deficient cell line was more sensitive to GCV, primarily at high concentrations.  
Interestingly, the proficient HCT116 cells actually accumulated more GCVMP in their 
DNA than their MMR-deficient counterparts at similarly toxic concentrations.  Depletion 
of MLH1 by siRNA, a required MMR protein, sensitized two other cell lines, but only at 
high concentrations of GCV.  siRNA resulted in depletion, but not complete elimination 
of MLH1, so basal MMR activity may still have been able to occur.  The fact that the 
sensitization of MMR-deficient cells occurs primarily at high concentrations suggests that 
a threshold of damage exists where other pathways become overwhelmed and cell death 
is initiated.  We must also consider the fact that while cells deficient in MLH1 are MMR 
deficient, MLH1 is known to participate in a variety of other pathways such as base 
excision repair, cell cycle checkpoints, and apoptosis (9-11).  Future studies aimed at 
distinguishing the role of MLH1 in MMR vs. other DNA damage response pathways will 
help to elucidate the exact function of MLH1 in GCV cytotoxicity. In yeast, depletion of 
another required MMR protein, MSH2, conferred the same degree of sensitivity to GCV 
as deletion of MLH1, suggesting that the difference in sensitivity is indeed due to MMR.   
We do not believe that MMR is able to protect cells from GCV cytotoxicity by 
removing GCVMP from DNA.  We have shown that MMR-proficient cells had higher 
levels of GCVMP incorporation than the MMR-deficient cells at equitoxic 
concentrations.  Excision of GCVMP from DNA has not been demonstrated directly, and 
any observed decrease in the amount of GCVMP in DNA of MMR-proficient HCT116 
cells could be accounted for by an increase in cell number.  While it is possible that rapid 
excision of some of the GCVMP residues from DNA by MMR during replication may 
occur, clearly a significant amount of GCVMP remains.  This suggests that MMR 
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decreases GCV cytotoxicity by correcting some other GCV-induced DNA damage.  
MMR is responsible for correcting mismatched nucleotides in DNA which, if left 
unrepaired, could result in mutations.   
In Chapter IV, we present studies of specific DNA lesions resulting from GCV 
treatment by characterizing the ability of GCV to induce mutations in DNA.  GCV 
induced a dose-dependent increase in mutation frequency, with a predominance of 
GC TA mutations.  Because mutation frequency only increased at concentrations of 
GCV >IC50, it appears unlikely that mutations are solely responsible for inducing cell 
death.  Despite the fact that lower concentrations of GCV did not induce an increased 
total number of mutations, they did result in an increased percentage of specific GC TA 
transversions, therefore cytotoxicity may be due to the nature of the induced mutations 
and not the overall number of mutations.  These specific mutations were induced in both 
MMR proficient and deficient cell lines, and the MMR proficient cell lines (HCT116 1-
2tk and U251tk) had a higher proportion of these mutations.  These data suggest that 
these specific mutations are the result of misincorporations which are not readily 
repairable by MMR.  The decrease in proportion of other types of mutations suggests that 
MMR repairs these, leaving a higher percentage of the GC TA mutations.  A study in 
NIH 3T3 cells determined relatively low repair rates for G:A (35%) and C:T (80%) 
mismatches as compared to G:T mismatches (100%) (12), so these misincorporations 
might be more prone to remain unrepaired.   
  A report of the solution structure of GCV in oligonucleotides illustrated that the 
phosphate-sugar backbone of GCV-containing DNA was kinked at the site of GCV 
incorporation (13).  Because GCV is an acyclic deoxyguanosine analog, the open sugar 
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presumably would give GCV-containing DNA more flexibility, which may allow DNA 
to rotate in such a way that it promotes errors in polymerase insertion of nucleotides.  We 
observed a high percentage of two specific C A mutations (C20A and C48A) following 
GCV exposure.  The high incidence of these specific mutations in three different cell 
lines suggests that the structure of these particular sequences of DNA make it more likely 
for the substitution of an adenosine in place of a cytosine.  This could be due to the 
acyclic nature of GCV which may allow more flexibility of the DNA structure.   Due to 
the small coding sequence of the supF cDNA, it was not possible to evaluate sequence-
specific effects in this study, but would be of interest in future studies. 
The oxidized purine 8-oxoguanine (8oxoG), a DNA lesion resulting from reactive 
oxygen species, is able to incorrectly base pair with A.  If this mispair is not repaired, it 
also results in a GC TA transversion.  Oxidation of the guanine at C8 turns N7 into a 
hydrogen bond donor, and this allows a 8oxoG:A base pairing which does not disrupt 
either the polymerase active site or the DNA structure (14,15).  Because there is not a 
major alteration in structure as would occur with a G:A base pair, 8oxoG:A mispairs 
readily evade proofreading.  It is possible that the GC TA mutations observed following 
treatment with GCV are a result of A being incorrectly inserted across from a GCV, as 
the loss of the structural constraint of a cyclic sugar ring may allow GCV to assume a 
different conformation which allows non-canonical basepairing capable of avoiding 
repair as well. This mechanism would require that the GC TA mutations we detected 
were the result of GCVMP present in template DNA.  While we believe the conditions 
favored incorporation of GCVMP into the nascent strand only, the possibility that the 
plasmids were replicated more than once in the human cells cannot be ruled out.   
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Although very similar in structure to GCV, neither CdG nor PCV were able to 
increase mutation frequency or the relative proportion of GC TA or any other type of 
mutations.  The specific C20A and C48A mutations did not occur following exposure to 
either CdG or PCV.  CdG is not acyclic, supporting our hypothesis that it is the flexibility 
of the acyclic sugar which allows GCV to induce these mutations.  PCV is also acyclic, 
however, it did not induce mutations.  The only difference in structure between PCV and 
GCV is that PCV has a carbon instead of an oxygen on the acyclic ring, and it is possible 
that the removal of the oxygen decreases hydrogen bonding necessary for mutations to be 
induced. If increased flexibility is involved in GCV’s formation of mismatches, the lack 
of an oxygen on the sugar ring of PCV may decrease flexibility and retain the structural 
constraint provided by an intact sugar ring and not allow for the interaction to occur.  In 
addition, PCV causes significantly greater inhibition of DNA synthesis than GCV.  In 
primer-template assays, PCVTP has been reported to be incorporated into DNA less 
efficiently than either ACVTP or GCVTP by DNA polymerases α, δ, and ε and, although 
PCV is not a chain terminator, further extension after incorporation of PCV is reluctant 
(16).  PCVTP is a poor inhibitor of polymerases, so it likely inhibits DNA synthesis after 
incorporation into DNA.  Since synthesis of DNA would be required for induction of 
mutations, this inhibition would result in a decreased mutation frequency as observed 
with PCV.   
We must also consider the fact that this mutation assay involves the replication of 
plasmid in both human cell lines and bacteria, and we cannot determine in which 
organism these mutations were created.  This pattern of mutations is unique to GCV and 
not simply an artifact of plasmid replication in bacteria, as we have performed this assay 
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with many other drugs and have never obtained similar results.  Future experiments 
characterizing mutations in chromosomal DNA in human cells will verify these results 
and indicate where these mutations are being generated.  Reports that GCV is genotoxic 
and carcinogenic in animal models support our findings that it can induce mutations in 
replicating plasmid DNA. 
Although the studies presented in this dissertation are in the context of gene 
therapy for cancer, it is also important to note the GCV is widely used to treat 
cytomegaloviral infections in immunocompromised patients.  Animal studies indicated 
that GCV is both mutagenic and carcinogenic, while rats and mice exposed to 2 to 8-fold 
more ACV or PCV than what is administered to humans did not have a significant 
increase in the incidence of tumors [reviewed in (17)].  It will be important to clarify how 
these experimental findings translate to the clinical setting in order to identify when the 
risks outweigh the benefits.  In a small study of 7 AIDS patients who were treated with 
the anti-retroviral nucleoside analog azidothymidine, peripheral lymphocytes were 
examined for chromosomal aberrations and it was determined that 8% of lymphocytes 
had aberrations while the rate of aberrations was only 0.5% in untreated AIDS patients 
(18).  Similar studies monitoring patients treated long-term with GCV for chromosomal 
aberrations, sister chromatid exchanges, gene mutations, and incidence of cancer should 
be conducted.   
Not only do the small changes in structures of these drugs result in different 
effects on fidelity of DNA replication, but they all cause different patterns of cell cycle 
progression.  Due to its strong inhibition of DNA synthesis, PCV arrests cells in S phase 
during drug incubation.  In contrast, cells treated with either GCV or CdG are able to 
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complete one cell division cycle after drug exposure because they do not inhibit DNA 
synthesis, and they subsequently arrest in the second S or G2/M phases, respectively.  
Both GCV and CdG have the ability to induce multilog cytotoxicity, suggesting that it is 
the ability to complete one round of the cell cycle with the analog present in DNA which 
results in increased cell killing as compared to other chemotherapeutic agents.  If cells 
continue to divide without recognizing the presence of nucleotide analogs in their DNA, 
the collision of the replication machinery with the analog may induce damage too severe 
for repair and make cell death inevitable.  DNA repair varies depending upon whether the 
lesion is in the template or occurs during nucleotide insertion in the nascent strand, as 
most repair processes, such as MMR, repair mistakes in the newly synthesized strand and 
few others, such as transcription coupled repair, recognize lesions in the template (19).  
Frequency of misincorporations at modified nucleotides depends upon whether the 
modified nucleotide is in the template or as the incoming triphosphate (20,21).  Because 
GCVMP is present in DNA of cells after they have completed one round of DNA 
replication, it is not completely excised by repair pathways involved in proofreading 
newly synthesized DNA.  This would suggest that any repair which may occur is initiated 
following the recognition of GCVMP in the template strand.  My studies demonstrating a 
second increase in γ-H2AX foci occurring with similar timing to the observed S phase 
arrest and immediately following an increase in Rad51 foci suggest that stalled 
replication forks are induced.  DNA replication machinery may be unable to situate 
properly on DNA with GCVMP incorporated to continue replication past the lesion, 
resulting in a stalled replication fork.  Rad51 is then recruited to re-start the stalled fork 
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but cannot get past the lesion, leading to the accumulation of lethal HRR intermediates 
and ultimately cell death. 
The data presented here suggest a variety of mechanisms to modify clinical 
therapy with GCV.  Perhaps the most successful clinical trials of HSV-TK/GCV gene 
therapy have been in prostate cancer (22), one of many human tumor types which are 
deficient in DNA damage response pathways, such as MMR (23,24).  It has been 
reported that 2 to 50% of prostate cancers are defective in MMR (25).  The data 
presented here suggest that MMR deficient tumors would respond better to HSV-
TK/GCV treatment than MMR proficient tumors since MMR deficient cells are more 
sensitive to GCV.  Although the data presented here demonstrate increased sensitivity in 
MMR deficient cells occurred with high concentrations of GCV, these concentrations 
represent clinically relevant doses.   In addition, the yeast screen suggests that tumors 
defective in certain checkpoint pathways would also respond better to GCV.  Since 
normal tissues are generally proficient in these pathways, targeting MMR and checkpoint 
defective tumors would improve selectivity of this therapy.  These studies also suggest 
other pathways, such as HRR, could be targeted in combination with GCV treatment to 
enhance GCV cytotoxicity.  Cells that lack BRCA1 or BRCA2 function are deficient in 
HRR and exhibit increased sensitivity to DNA damaging agents mytomycin C and 
etoposide and may also be more sensitive to GCV (26-29).  Because overexpression of 
Rad51 is common in malignant cells (30), it will be interesting to explore the effect of 
this overexpression on GCV cytotoxicity in human cells. 
In the future, it will be important to determine the extent and timing of DNA 
damage induced by CdG.  It is my hypothesis that CdG will also induce high amounts of 
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DNA damage, and that this damage will occur similarly to that observed with GCV.  If 
the multilog cytotoxicity is due to the fact that these analogs remain undetected in DNA 
until the second round of DNA replication following exposure, it will be interesting to 
characterize which, if any, repair pathways are initiated immediately preceding cell cycle 
arrest or if this is simply caused by failed DNA synthesis.  Further characterization of the 
mechanism by which GCV and CdG cause multi-log cytotoxicity may provide the basis 
for development of new anti-tumor agents with the same ability which may be superior to 
those in use today. 
Although the research presented here has added significantly to the knowledge of 
GCV’s mechanism of action, there remain questions which will require further research 
to answer.  It will be of interest to determine if GCV produces the same abundance of 
GC TA mutations in mammalian chromosomal DNA, which could be accomplished by 
using an assay for mutations induced in the hypoxanthine-guanine phosphoribosyl 
transferase locus by evaluating resistance to 6-thioguanine.  A much more complex issue 
will be to determine why these specific mutations are induced by GCV.  It will be 
beneficial to more fully understand the consequence of GCV incorporation on DNA 
structure and characterize the interaction of GCV, in the triphosphate form as well as the 
monophosphate incorporated into DNA, with polymerases and other components of DNA 
replication machinery.  This will help determine if these mutations arise from addition of 
the incorrect nucleotide opposite GCV, replication errors caused by changes in structure 
of GCV-containing DNA, or another mechanism.       
In addition to understanding the nature of the lesions produced by GCV, it will 
also be of great interest to further investigate repair pathways involved in responding to 
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and repairing this damage.  My research has generated preliminary data implicating 
several repair pathways, such as HRR, cell cycle checkpoints, and MMR, and future 
work will characterize the exact involvement of these pathways in responding to GCV-
induced damage.  For example, it will be important to determine if depletion of proteins 
essential for HRR in mammalian cells change sensitivity to GCV or induction of DNA 
damage.    
There have been very few published reports of activation of DNA damage 
signaling pathways as a result of GCV exposure.  The involvement of specific pathways 
can be determined by characterizing activation of proteins such as ATR, Chk2, p53, and 
caspases.  Elucidation of these signaling pathways may aid in the determination of what 
recognizes the DNA lesions produced by GCV and the cause of the observed S phase 
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